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Abstract
PATHOGENESIS, PATHOLOGY AND CHEMOTHERAPY OF
EXPERIMENTAL LEGIONELLA PNEUMOPHILA INFECTION
by
Arthur O. Tzianabos
University of New Ham pshire, D ecem ber, 1989

Legionella pneum ophila is the causative ag en t of a severe, often fatal
pneum onic illness known a s Legionnaires' disease. T he m echanism s by which
L. pneum ophila a tta c h e s to U937 (transform ed hum an m acrophage-like cells)
an d to MRC-5 cells (sem i-continuous hum an lung fibroblasts) w ere
investigated. Experim ental p aram eters for ad h eren ce a ssa y s w ere established
prior to blocking studies d esig ned to identify microbial adhesins an d /o r
eukaryotic receptors that m ediate bacterial attachm ent to target cells. Results
from th e se stu d ies indicated that a lectin-like com ponent (s) a sso c ia te d with L.
pneum ophila m ay be responsible, at least in part, for microbial a d h e re n c e to
th e se eukaryotic host cells. Erythromycin is the drug of choice for th e treatm ent
of clinical legionellosis; however, difficulties with this antibiotic h av e been
reported resulting in the n eed to seek alternative therapeutic regim ens. In th e se
stu d ies, the effect of clinically relevant antibiotics that inhibited bacterial ceil
wall, protein and DNA synthesis of this pathogen w as evaluated in vitro by
growth and viability studies a s well a s morphologically by negative stain,
xv

scanning and thin-section electron microscopy. Of th o se te ste d , cefotaxim e, an
antibiotic of limited value in clinical trials, w as m ost effective.

The pathogenicity

of L. pneum oohila w as a s s e s s e d by LD50 and bacterial growth estim ations in
the chick embryo anim al system in ovo. In addition, histopathological and
electron m icroscopic exam ination of the cellular and sub-cellular pathology
induced in the org an s of em bryos previously infected with 100 tim es the yolk
sa c (YS)LD 50 of L- pneum ophila w as m ade a s a prelude to chem otherapeutic
treatm ent with a range of clinically putative antimicrobial ag en ts. The promising
new quinolone derivative, ciprofloxacin, w as m ost effective in th e se trials.
R esults from th e se studies m ay be indicative of novel preventative and control
m e a su re s for the therapy of hum an Legionnaires' disease.

xvi

Legionella p neum ophila, serogroup 1 , strain Nottingham N7. Scanning
electron m icroscropy (SEM) preparation. Bar=0.5pm.

xvi i

Section I

The Natural History of Legionnaires' Disease

1.1 Preface.

L e g io n n a ire s'd ise a se is a sev ere illness of hum ans which

often occurs in spectacu lar outbreaks. Although an extensive d a ta b a se
concerning all a sp e c ts of legionellosis has been established since th e outbreak
in Philadelphia 13 years ago, the m echanism s by which the subsequently
described cau sativ e agent, Legionella pneum ophila, induces d ise a se are not
fully understood. This study exam ines the pathogenesis of this organism at the
host, cellular a n d sub-cellular levels and defines th e role of clinically relevant
antibiotics in th e d ise a se p rocess.
1.2 Historical perspective. The outbreak of a se v e re form of a c u te lobar
pneum onia during an American Legion Convention held at the Bellevue
Stratford Hotel in Philadelphia in July 1976 w as the precipitating factor which
led to the isolation and identification of this previously unrecognized hum an
pathogen. During this epidem ic, 29 of the 182 legionnaires who b ecam e ill,
died. An additional 39 individuals who were in or p a s se d by the hotel
developed pneum onia. In all, 34 died from the d ise a se or asso ciated
com plications during this outbreak (49). The illness, eventually nam ed
Legionnaires' d ise a se , took its nam e from the Philadelphia outbreak. Initially, a
viral etiology w a s su g g ested d u e to the influenza-like sym ptom s m anifested in
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th e s e people. Indeed, influenza and other bacterial pneum onias are still
com m on diagnostic considerations by clinicians presented with sym ptom s of L.
pneum ophila infection (99).
Failure to immediately isolate the cau sativ e agent following the
Philadelphia epidem ic cau sed th e new s m edia to heighten concerns about the
p re se n c e of a new microbial killer. T hese em bellished reports undoubtedly
expedited the epidem iological a n d microbiological investigations following the
outbreak and contributed to su b seq u en t recognition of this important hum an
pathogen. Although investigators at the C enters for D isease Control (CDC) in
A tlanta announced the cau se of th e d isease six m onths after th e outbreak, they
could not identify th e mode of transm ission but only pointed out that a com m onso u rc e epidem ic h ad occurred.
The inability to stain or grow the organism using conventional
microbiological p ro ced u res proved the main problem s in identifying the
etiological agent of th e disease. Dr. Joseph M cDade at CDC finally isolated the
organism using tech n iq u es established for the recovery and identification of
rickettsiae. The yolk sa c s of em bryonated e g g s w ere inoculated with lung
s a m p le s from fatal c a s e s and th e bacteria w ere visualized by G im enez stain
which contains carbol fucshin rather than safranin. The latter fails to stain
Legionella sp ecies and, a s it is th e usual com ponent of the gram stain, offers
explanation of th e failure to visualize the ag en t initially (85). It w as
subsequently show n that the organism and the d is e a s e it c a u s e d were not new,
an d previously unresolved epidem ics were retrospectively attributed to this

2

organism . Among th e se w as an outbreak of a febrile illness with a high attack
rate that occurred in Pontiac, Mi. in 1968 and, due to its non-pneum onic form,
w as later called "Pontiac Fever" (59). The explanation for the variability of
sym ptom s of Legionnaires’ d ise a se and Pontiac Fever is unknown. The
spectrum of d is e a s e c a u se d by this and related m icroorganism s is term ed
legionellosis.
After attem pted cultivation on 17 commonly used bacteriological media,
Feeley et al. (43) reported that Mueller-Hinton a g a r supplem ented with 1%
hem oglobin an d 1% IsovitalexR supported sp a rs e L. pneum ophila growth.
F eeley-G orm an ag ar, which contained ad d ed L*cysteine hydrochloride and
soluble ferric pyrophosphate, w as an im provem ent upon this medium (42).
Finally, Edelstein (29) introduced a useful but expensive solid medium which
contained a-k eto g lu tarate (BCYEa) that supported substantial bacterial growth
after a 48-72 h incubation period at 37° C. This rem ains th e medium of choice
for th e cultivation of legionellae in clinical and research laboratories.
S u b seq u en t investigations have dem onstrated that L. pneum ophila is an
environm ental organism readily found in stream s, lakes an d potable w ater and
w hen delivered in appropriate aerosolized form enters the respiratory tract of
h u m an s and replicates within alveolar m acrophages of the lung (13, 111). Air
conditioners, humidifiers, evaporative co n d en sers, cooling tow ers and other
w ater sy stem s cap ab le of generating aerosols are potential sources of d iseaseH um an-to-hum an sp re a d has never been recorded.
Experimental study of the pathogenic a s p e c ts of the organism h as
3

utilized a num ber of different laboratory anim als, but to date none have fully
sim ulated all a sp e c ts of legionellosis. G uinea pigs, rats, mice, rabbits and
m onkeys have been experimentally infected with L. pneum ophila by a num ber
of different inoculation routes and th e se manifest som e, but not all the
sym ptom s of clinical d ise a se . G uinea pigs are u sed m ost extensively in such
stu d ies, but restricted availability, high c o sts and legislative p re ssu re s have
forced re sea rc h ers to se e k alternative sy stem s to study path o g en esis of the
organism .
1.3 The Organism:
1.3.1

T a x o n o m y a n d n o m e n c la tu re .

The classification an d nom enclature

of this organism is difficult. Brenner et al. (15, 16) u sed DNA homology studies
a s th e primary tool to establish that the Legionnaires' d ise a se bacterium of the
Philadelphia outbreak w as a m em ber of a new family (Leqionellaceael of the
g e n u s Legionella and sp e c ie s pneum ophila.

Serological diversity within this

s p e c ie s is well established an d num erous additional sp ecies, su b -sp e c ie s and
sero g ro u p s h av e been d escribed since that time (Table 1.1).
The diversity of the g e n u s has b een noted (15) and attributed to the
failure of traditional biochem ical, immunological and genotypic techniques to
yield corroborative results. Analysis of fatty acid and isoprenoid quinone
co n ten t have b ee n useful, but do not accurately differentiate all sp ecies a n d are
not appropriate for use o utside of a large research laboratory (15). The
determ ination of DNA related n ess has b een and rem ains the main criterion for
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Table 1.1

Taxonom y and classification of the g e n u s L e g io n e lla *

S p e c ie s

L. pneum ophila^

L. m icdadei 2
L. bozem anii 3

L. dumoffii3
L. gormanii 3
L. lo n g b each ae

L.
L.
L.
L.

jordanis
oakridgensis
wadsworthii
feelii

L.
L.
L.
L.
L.
L.

sainthelensi
an isa
m aceachernii
jam estow niensis
rubrilucens
erythra

S ero g ro u p

Isolated From
H um ans
Environm ent

1
2
3
4
5
6
7
8
9
10
11
13
14

Y es
Y es
Y es
Y es
Y es
Y es
Y es
Y es
Y es
Y es
Y es
Y es
Y es

Y es
Y es
Y es
Y es
Y es
Y es
Y es
No
Y es
Y es
No
No
No

1
2

Y es
Y es
Y es

Y es
Y es
No

1
2

Y es
No
Y es
Y es

Y es
Y es
No
No

1
2

Yes
No
Y es
Y es
Y es

Y es
Yes
No
Y es
No

No
No
Y es
No
No
No

Y es
Y es
Y es
Y es
Y es
Y es

(continuation)
L. hackeliae

L.
L.
L.
L.
L.
L.
L.
L.
L.
L.
L.
L.

1
2

spiritensis
parisiensis
cherrii
steigerwaltii
santicrucis
israelen sis
birm ingham ensis
cincinnatiensis
m oravica
brunensis
quinlivanii
tu cso n e n sis

Y es
Y es

No
No

No
No
No
No
No
No
Y es
Y es
No
No
No
Y es

Y es
Y es
Y es
Y es
Y es
Y es
No
No
Yes
Yes
Yes
No

‘A dapted from reference 136, Winn, W. C. Jr., Clin. Microbiol. Rev.
1|_. pneum ophila contains th ree su bspecies: L. oneum oohila su b sp e c ie s
p n eu m o p h ila. L. pneum ophila su b sp ecies pascullei an d L. pneum oohila
su b sp e c ie s fraseri.
2Alternate g e n u s nam e: Tatlockia.
3Alternate g e n u s nam e: Fluoribacter.
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classification. However, practical identification of Legionella
sp e c ie s h as d ep en d ed on phenotypic characteristics which include gram
reaction a s well a s growth on BCYEa with added L-cysteine and the ab sen ce of
growth on blood ag a r or BCYEa without added L-cysteine.
The classification of Legionella sp ecies has b een som ew hat
controversial. D isagreem ent continues a s to the d e g re e of genetic divergence
that constitutes th e establishm ent of a sep arate sp e c ie s a s well a s the disparity
with which resea rch e rs have applied criteria to m ake th e se distinctions. Brown
et al. (54) pro p o sed alternate criteria for classification p urposes in which two
new g en era, Tatlockia an d Fluoribacter. w ere created. T h ese would contain
organism s otherw ise called L. micdadei and the autofluorescing Legionella
sp ecies L. bozem anii. L. dumoffii and L. gormanii. respectively (Table 1.1).
However, this sch em e h a s not found universal accep tan ce and m ost workers
accep t the single g en u s terminology of Legionella within which all sp ecies are
located. It is clear that further work is n ecessary to establish uniform guidelines
for the classification of th e legionellae and related sp ecies.
1.3.2

Morphological characteristics.

Morphological properties of L.

pneum ophila a re shown in Table 1. 2 . Transm ission electron microscopy of thinsectioned L. pneum ophila cells has dem onstrated th e typical morphological
characteristics asso ciated with gram -negative bacteria (105). L. pneum ophila
organism s w ere shown to be pleomorphic gram -negative rods that m easure 2
to 20 pm in length and 0.3 to 0.9 pm in width. Artificial m edia giving poor or
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Table 1.2

M orphological properties of L. p n eu m op h ila^

Short rods (from autopsied lung 0.6 x 1-2 pm, from a g a r 0.4 x 2-3 pm)
T ap ered en d s
V acuolated surfaces, convoluted or sm ooth surfaces
Long form s fin vivo up to 20 pm in length, in vitro >50 pm)
Internal PBH granules-deform ed in freezed fracture
Division by n o n sep tate binary fission
Flagella and fimbriae (pili) present
Blebs an d g ran u les on surface subunits, no evidence of acid polysaccharide
c a p su le
F-1 antigen (serogroup specific) located at bacterial su rfaces
Limiting cell envelope, "unit m em brane", 10 nm thick
Peptidoglycan-like m ucopeptide layer p resen t after partial plasm olysis
P lasm a m em brane, "unit m embrane", 10 nm thick
Rich in ribosom es, 25 nm diam eter
1A dapted from reference 107, Rodgers, F.G., Legionellosis.
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slow bacterial growth resulted in organism s with an elongated or filam entous
form with tapered en d s. T hose rods visualized from autopsied lung w ere
consistently shorter (21,105).
The cytoplasm of each organism is enclosed within a double cell
envelope of approximately 25 nm thickness with an electron-lucent zone or
periplasm betw een th e inner an d outer m em branes indicating, like the aquatic
pseu d o m o n ad s, an apparent a b s e n c e of peptidoglycan (105).

However,

peptidoglycan an d diam inopim elic acid have b e e n d em onstrated following
partial plasm olysis an d enzym atic digestion of the organism by electron
m icroscopy and by other biochemical techniques (46, 105, 107, 108).

The

outer m em branes of organism s contain substantial am ounts of the bacterial
lipopolysaccharide com ponent, 2-keto-3-deoxyoctonate (46).
Cytoplasm ic contents consist of evenly dispersed, electron-dense
ribosom es, each of 25 nm diam eter, arranged in small groups or polysom es
and a fine skein of nuclear material (105, 110, 111). Electron-lucent vacuoles
have b een dem onstrated as a regular feature of the cytoplasm of L
pneum ophila w hether present in hum an lung cells, guinea pig spleen,
peritoneal m acro p h ag es or from bacteriological m edia (107). The reported size
of th e se vacuoles varied from 30 to 200 nm (13) but larger forms up to 0.5 pm
have b een found (107). T hese structures have been confirm ed a s poly-(3hydroxybutyrate (PBH) granules by their ap p earan ce in freeze-fractured
preparations (107, 108).
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Negative-stain and scanning electron microscopy of L. pneumophila
revealed bacterial cells with nonparallel sides, tapered e n d s and smooth
undulating surfaces. Flagella an d fimbriae (pili) have b e e n dem onstrated in
vitro a s surface a p p e n d a g e s of L. pneumophila (110). T h e p resen ce of small
blebs and evaginations of the outer m em brane have been noted on the
surfaces of organism s by thin-section, scanning and freeze-fracture electron
microscopy, but an extracellular mucopolysaccharide layer has not been
detected. In addition, freeze-fracture electron microscopy of L. pneumophila
dem onstrated four short ridges enclosing the bacterial cytoplasm which
corresponded to th e double-unit mem brane s e e n in thin-sectioned material
(107, 108). Fractured aspects of the peptidoglycan were not evident in the
intramembranous region of bacilli even after partial plasmolysis.
Poly-p-hydroxybutyrate granules were surrounded by a non-fracturable
m em brane evident a s a single ridge in freeze-fracture preparations and
confirmed reports of electron-lucent vacuoles in thin-sections. In keeping with
the nature of PBH granules, contents of the granules in L. pneumophila
underwent plastic deformation a s an artifact of the fracture process an d were
evident a s long, drawn out structures (107,108).
1.3.3

Biochemical properties. L. pneum ophila is a non-spore forming,

aerobic, non-acid fast organism.

All species of the g en u s dem onstrate weak

catalase and peroxidase activity. L. pneumophila also e x p re s s e s gelatinase,
phospholipase an d p-lactam ase a s well a s th e ability to hydrolyze starch. Many
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reports describe a num ber of exo pro teases produced by the organism and
th e se d eg rad e a wide variety of proteins (10, 79). Keen an d Hoffman (79) have
isolated and partially characterized an exoprotease of L. pneumophila that
exhibited cytotoxic an d hemolytic activity.
L. pneumophila contains an unusually large proportion of branchedchain fatty acids located in the cell wall (15) but reports demonstrating the
p re se n c e of an extracellular acid polysaccharide layer by ruthenium red
staining have b een contradictory (66, 105). The organism has been shown to
p o s s e s s a high molecular weight antigen or lipopolysaccharide (LPS), termed
the F-1 antigen (34, 76) which had endotoxic activity, inhibited serological
reactions and w as localized on the surface of the bacterium. The LPS of L.
pneum ophila serogroup 1 w as found to be tightly bound to th e major outer
m em brane protein (MOMP), reacted specifically with the s e ra of patients with L.
pneum ophila serogroup 1 infection and w as distinctly different from that of most
enteric bacteria (136).
T he MOMP of L. pneumophila has a molecular weight of 24 to 29
kDa (18, 53, 67, 76, 89) and is expressed on the surface of the bacterium (34).
Reports have s u g g e ste d that the MOMP may be associated with LPS (67) and
peptidoglycan (52). G abay and Horwitz (52) showed that this molecule formed
ion-permeable ch an n els similar in function to those found in Escherichia coli
upon exposure to lipid m em branes. Butler et al. (18) su g g ested that th e MOMP
is part of a larger, four sub-unit 95 kDa complex.
Investigations have shown that amino acids are th e major source of
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energy for growth (55, 80), although the specific amino acid requirements are
a s yet undetermined. However, it is generally agreed that arginine, threonine,
methionine, serine, isoleucine, valine, and cysteine are necessary. In addition,
several groups have dem onstrated that L. pneumophila can be grown in
chemically defined m edia com posed of amino acids (55, 94). While purines,
pyrimidines, vitamins an d other growth factors are not required, it is known that
this organism h as an unusually high requirement for L-cysteine.
The Krebs cycle is the primary route for carbon assimilation and energy
production for L. pneumophila (55, 68, 122). These studies have shown that all
the enzym es of this cycle were present but those of the glyoxylate shunt were
marginal or ab sen t in cell-free extracts of this bacterium.
Legionellae do not appreciably catabolize carbohydrates. Early reports
show ed negative su gar fermentation results but su b se q u e n t studies indicated
that the Entner-Douderoff and pentose phosphate pathw ays but not the
Embden-Meyerof pathway functioned to a limited d e g re e in glucose catabolism
(134). However, the gluconeogenic anabolic enzym es of the Embden-Meyerof
pathway w ere responsible for sugar synthesis (55).
L. pneumophila growth is en h an ced by trace metals, most notably ferric
iron, but this may not be an absolute requirement (102,121). Other important
metals include Cu, Mg, Mn, Co, Ca, Mo, Ni, V, and Zn. In addition, R ee v es et al.
(103) have reported the a b s e n c e of phenolate or hydroxamate ferric-binding
com pounds in Legionella species. The function of charcoal and a-ketoglutarate
in the growth media of this organism h a s been questioned. Som e investigators
12

believe that th e se com pounds neutralize oleic acid produced in th e media upon
autoclave sterilization while others have su gg ested that they may serve to
scav en g e toxic oxygen radicals released from the y e a s t extract present in the
medium upon exposure to fluorescent light (69). However, the precise nature of
this requirement h a s not been elucidated.
The electron transport chain of L. pneumophila is c o m p o se d of
cytochrom es c, b, a and d types but th e organization of the respiratory chain
remains undetermined (68). The concentrations of th e se heme-containing
proteins were much lower in Legionella com pared with those of other aero bes
such a s P se u d o m o n a s or Cam pylobacter. R esearch ers have concluded that
the respiratory chain is quite complex in L. pneumophila but is punctuated by at
least three terminal oxidases (68).

The biochemical properties of L.

pneum ophila are summarized in Table 1.3.
1.3.4

Physico-chemical properties. The legionellae have an optimum pH

range for growth of 6.7 to 6.9 in BCYEa but may grow in other m ed ia with pH
values a s low a s 6.0 (47, 55). Clinical isolates have an optimal tem perature
range of 35 to 37° C but environmental isolates prefer an optimum of 30° C.
Isolation of the legionellae from water at 50 to 65° C h a s been reported (47).
1.3.5 Genetics. Genetic analysis of L. pneumophila has proved difficult. The
fastidious nature of the organism an d lack of conventional genetic transfer
system s for the legionellae have limited our knowledge in this a re a .

Plasmids ■

have been found in L pneumophila but have not b e e n shown to contribute to or
detract from the virulent properties of the organism. Recent efforts to clone the
13

Table 1.3

Biochem ical properties of L. pneum ophila

-non-spore forming
-aerobic
-non-acid fast
-motile (most strains)
-high proportion of branched chain fatty acids in cell wall
-amino acids a s carbon and energy sources
-oxidase (+/-)
-catalase (+)
-peroxidase (+)
-nitrate reductase (-)
-urease (-)
-hippurate hydrolysis (-, most strains)
-gelatinase (-)
-B-lactam ase (+)
-ex op ro teases (+)

g e n e s for Legionella antigens in E. coli have b een successful (27, 37, 38). In
addition, Cianciotto et al. (23) were able to render a previously virulent strain of
L. pneumophila non-infectious for cell cultures through the genetic deletion of a
24 kDa surface protein. Studies such a s th ese may help further our knowledge
concerning the pathogenic m echanism s of this organism.
1.3.6

Environmental aspects.

The L e g io n e lla c e a e are ubiquitous in

natural aquatic habitats and m an-m ade water system s. L. pneumophila has
been isolated from lakes, stream s, rivers, cooling water, hot w ater and potable
water s y stem s (48, 86). There is conclusive epidemiological evidence that the
generation of aerosols from domestic and industrial air-conditioners,
evaporative co nd ensers, cooling, hot water and other aquatic sy stem s which
release micron-sized water droplets into the air serve a s potential sources for
legionellosis (86). An appropriate infectious d o se of L pneum ophila may be
delivered by aerosolized droplets 5 to 15 pm in diam eter which c a n readily
enter the nasopharynx an d penetrate alveolar airspaces of the lung.
L. pneumophila h a s been primarily isolated from warm or thermally
polluted freshwater system s. Although the organism h as been found in a wide
variety of aquatic niches, it is estim ated to comprise a very small portion of the
total bacterial population in the aquatic environment.
The association of Legionella with blue-green algae an d freshwater
protozoans including free-living a m o e b a e A can th am o eb a. T etrah vm en a and
Cvclidium sp ecies has b een dem onstrated (3, 113, 124). Such interactions
have been hypothesized to provide legionellae with an a b u n d a n c e of nutritional
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support and a host in which microbial num bers can be amplified. Evidence
p resented by Berendt (11) su gg ested that the survival of L. pneum ophila in an
aerosolized form w as en h an ced by its association with various sp ecies of the
blue-green algae, Fischerella. and that dissemination aw ay from the source of a
g e n e ra te d aerosol may be aided by particular algal com ponents. Results from
other studies (127) indicated that legionellae may be carried in aerosolized
form in cooling tower plumes 20 to 50 kilometers downwind and illustrated the
potential danger p o sed by this pathogen.
T he eradication of legionellae from water sy stem s is rarely possible and
studies should center on determining acceptable microbial densities for the
organism. Effective biocidal treatments are being investigated for u s e a s control
and preventative m easu res. The most effective potable water treatm ents have
been shown to b e hyperchlorination, especially of hot w ater supplies and
heating to above 50° C. Acceptable treatm ents for non-potable water included
chlorination, use of quaternary ammonium com pounds an d halam ines (118).
1.4

The Disease

1.4.1 Epidemiology. Legionellosis can exist in two forms: the se v e re
pneum onic type with associated high fever known a s Legionnaires' d ise a se
and th e non-pneumonic form known a s Pontiac Fever. Table 1.4 lists the
sym ptom s for th e se conditions. The d ise a se can occur a s epidemics, sporadic
c a s e s , or nosocomial infections. Epidemic legionellosis h as been docum ented
in many countries including the United S tates, Great Britain, Spain, The
Netherlands, Germany, Sw eden, France, C a n a d a and Italy and show s an
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Table 1.4 Comparison of symptoms of patients with Legionnaires'
disease or Pontiac Fever.

Sym ptom

Cough
Sputum production
D y sp n ea
Hemoptysis
Myalgias
Upper respiratory symptom s
Headache
Confusion
N a u se a or vomiting
Diarrhea
Abdominal pain
Fever

Legionnaires'
D isease

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
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Pontiac
Fever

Y es
No
No
No
Yes
No
Yes
Yes
Yes
Yes
No
Yes

increase in incidence during the su m m er months of July, August and
S ep tem b er (Figure 1.1). L. pneumophila serogroup 1 is responsible for 85% of
reported c a s e s of legionellosis while L. micdadei c a u s e s approximately 6%
(136). A number of sp ecies of Leoionella have b een isolated from human and
environmental sources.

The most recognized form of legionellosis,

Legionnaires' d isea se, h as an incubation period of 2 to 10 d ay s with an attack
rate of 1 to 5% an d a case-fatality ratio of 0 to 40% (84,139). It h a s been
estim ated to be responsible for 1 to 29% of community acquired pneumonia.
A s se s sm e n ts of this nature have been difficult du e to the environmental nature
of Legionella and the difficulty in establishing an etiology for m any undiagnosed
pneum onias. Table 1.5 illustrates the clinical presentation of legionellosis.
The d is e a s e exhibits a predilection for immunocompromised individuals.
T he risk of developm ent of Legionnaires' d isea se increases in th e elderly and
in th o se who excessively smoke and/or drink alcoholic beverages. In addition,
underlying illnesses such a s diabetes mellitus, congestive heart failure,
malignancy, obstructive pulmonary d ise a se or u se of immunosuppressive
medication may increase susceptibility to this opportunistic pathogen.
It h as been dem onstrated that airborne transmission of aerosolized
organism s is the m echanism by which the organism and hence th e d isease
dissem inates, but identification of pin-point so urces of the infection in epidemic
legionellosis are often difficult. Investigation of the Philadelphia outbreak did
not conclusively dem onstrate the source of the epidemic, but stu dies showed
that attendance in a 14th floor hospitality room of the Bellevue-Stratford Hotel
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Figure 1,1 Average incidence of Legionnaires' d is e a s e c a s e s reported to the
CDC from 1978 to 1981. Note higher incidence during the sum m er m onths of
each year. Reprinted with permission from Legionellosis, S. M. Katz (ed.),
copyright C R C Press, Inc. Boca Raton, FI.

Table 1.5

Clinical presentation of le g io n e llo sis

Two form s: Legionnaires' disea se (LD) and Pontiac Fever (PF)
Genotypically and phenotypically identical

LD

N am ed for:

Philadelphia outbreak

Attack rate:

1-5%

Incubation period

2-10 days

Sym ptom s:

Pneumonia

Other o rg ans
affected:
Case:Fatality rate

Kidneys, G.l. tract, CNS
Variable 0-40%

20

PF

Pontiac out break
95%
1-2 days
Non-pneumonic

None

0%

may have b een a significant risk factor. However, the development of illness in
people who never entered the hotel but were in c lo se proximity w as suggestive
of airborne transmission. That evaporative c o n d e n s e rs and air handling
equipment have been identified a s th e source of o th er outbreaks further
substantiated this hypothesis (84, 86).
The first reported c a s e of Pontiac Fever w a s recognized retrospectively
following th e events of the Philadelphia epidemic. The Pontiac Fever outbreak
occurred in July 1968 in a health departm ent in Pontiac, Mi. an d this ep isod e
provided significant evidence of airborne transmission of organism s from a
evaporative co n d en ser (59). Between the time that the first illness was reported
until two d a y s later, 89 of the facility's 100 em ployees and 15 visitors b ec a m e
sick. All c a s e s had no common exposures outside th e building and people
working in all a re a s of the building w ere exposed. However, attack rates were
higher in p erso n s ex p o sed during the morning than in people newly ex p o sed in
the afternoon suggesting increased risk after the air-conditioning system w as
first turned on each day. S ubsequent investigation revealed that the central airconditioning unit for the building w as contaminated by an adjacent evaporative
condenser.
Similar instances have been documented w h ere burst exposure of
individuals to aerosols or air handling equipment contam inated with L.
pneumophila have led to illness.

Most notably, a study of recurrent

Legionnaires' d isea se in a hotel in Spain revealed that m em bers of married
couples who were the first to shower in the morning had contracted
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legionellosis in fi/e of six c a s e s (5). T h e s e data may indicate that inoculum size
of L. pneumophila is a contributing factor to the initiation of disease.
Sporadic c a s e s of legionellosis outnum ber epidemic c a s e s by a two to
one ratio. This ratio may even be higher given th e probability that only 0.8 to
2% of th e se c a s e s are reported each year. According to the surveillance
system of th e CDC, from the period of 1978 to 1981, sporadic c a s e s had b een
reported in every one of th e states of th e USA, occurred primarily in the sum m er
months and had an incidence ranging from less than 0.25 to more than 1.0
c a s e s per 100,000 people (Figure 1.2). Sixty-six percent of c a s e s were in
p erso ns g reater than 50 y ears old (84).
Tobin et al. (125) were the first to suggest that hospital water system s
other than cooling units could act a s reservoirs for L. oneum oohila.
S u b se q u en t investigations have substantiated that potable w ater is a potential
source of nosocomial or hospital-acquired legionellosis (1). Environmental
sampling in several hospitals has led to the isolation of L. oneumoohila an d
other sp ecies from a variety of sources including show er h eads, tap water,
medical drills an d respiratory therapy equipment (1, 4 ,1 7 ). Reports vary a s to
the incidence of hospital-acquired Legionella infections but th e s e range from 0
to a s high a s 30%. In general, investigators actively searching for Legionella as
a c a u s e of pneumonia ten d to find it to a greater frequency.
The incidence of nosocomial Legionnaires' d ise a se can be attributed to
the ubiquity of the organism in hospitals and the p resence of a susceptible
population. Haley et al. (63) have found that length of stay a n d compromised
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Figure 1.2 Reported sporadic c a s e s of legionellosis to the CDC from 1978 to
1981 indicating a v erag e incidence per 100,000 individuals per state. Reprinted
with permission from Legionellosis, S. M. Katz (ed.), copyright CRC P ress, Inc.
Boca Raton, FI.
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immunity w ere the g reatest risk factors for acquisition of d ise a se by patients.
Interestingly, the w idespread p resen ce of legionellae in water so u rces of
hospitals d o e s not correlate well with the incidence of disease. Explanations for
this phenom enon include colonization of water lines with non-virulent
legionellae, presen ce of sub-infective d o s e s of organism s and variations in the
susceptibility of patients. Further studies are n eed ed to determine the pre
existing conditions within a hospital which are most likely responsible for the
incidence of nosocomial Legionnaires' disease.
The m ost perplexing issues concerning the epidemiology of legionellosis
is the manifestation of two sep arate illnesses, Legionnaires' d is e a s e and
Pontiac Fever, from infection with the s a m e organism. No differences can be
attributed to the bacterium or to conditions surrounding outbreaks to explain
discrepancies in symptoms, attack rate or incubation period. It is possible that
either the infectious d o se for each d is e a s e varies or alternatively that patientrelated differences may be responsible. To date no evidence h a s accum ulated
to support either of th e s e hypotheses. Further work is needed to determine
whether this phenom enon is related to other pathogenic features exhibited by L,
p n eu m o p h ila.
1.4.2 Clinical features. Legionellosis is two to three times m ore common in
men than in women and infections in children are rare. The d is e a s e p resents
a s an atypical lobar pneum onia and h a s an incubation period of 2 to 10 days.
The infection begins with acute fever, rigors, h ea d a c h e and myalgia. Upper
respiratory tract symptom s are often a b s e n t and a non-productive dry cough
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may ap pear three to four days later. On occasions when sputum is produced it
is often non-purulent. D yspnea and respiratory difficulties a re common.
Extrapulmonary symptom s such a s gastroenteritis, fatigue an d confusion are
often reported and commonly lead to m isdiagnoses by clinicians (see Tables
1.4 and 1.5). Legionellae are difficult to isolate from respiratory secretions but
m ay be readily dem onstrated in direct lung biopsy by immunofluorescence.
1.4.3

Pathology.

X-ray radiographs of patients with Legionnaires' d is e a s e

have been variable an d do not uniquely identify Legionella pneumonia. An
a v e ra g e of three d ay s occurs between the on set of symptoms an d the
a p p e a ra n c e of radiographic pathology (40, 81). Deterioration of lung has been
s e e n in two-thirds of c a s e s and the most common features noted are the
a p p e a ra n c e of infiltrates and pleural effusions. Usually one lobe is affected but
bilateral involvement h as occurred in approximately one-quarter of reported
c a s e s (81).

The resolution of radiographic problems has often taken longer

than that of clinical recovery and may require an extended period of
convalescence. Post-mortem lung sam ples have dem onstrated the
developm ent of fibrino-purulent d isea se in one or both lungs with focal or lobar
consolidation, e d e m a , congestion and grey hepatization. In m ost c a s e s , a
fibrinous exudate is present in the pleural cavity. Macroscopic lesions are not
alw ays present but can include hemorrhagic a r e a s and focal a b s c e s s formation
(14).
Microscopic examination h as revealed a severe inflammatory resp on se
within the distal airsp a c e s of the lung. Terminal bronchioles and alveoli are
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filled with proteinaceous material, fibrinous exudate and contain numerous
m acro ph ages and polymorphonuclear leukocytes (PMNLs) presenting in
varying proportions. Proximal bronchi and bronchioles usually remain
uninvolved throughout the d isea se process. Alveolar d a m a g e with hyaline
m em b ran es and desquam ation of lining cells h as been noted in lung biopsies
(90, 136).
Shortly after the initial outbreak in 1976, Rodgers et al. (111) first
dem onstrated the p re se n c e of L. pneumophila within lung cells by electron
microscopy and described ultrastructural degenerative c h a n g e s asso ciated with
further dissemination of the organism into alveolar extracellular spaces. T hese
findings were subsequently confirmed by other ultrastructural reports which
described the intracellular nature of the organism (105, 106, 107).
Several investigators have dem onstrated that patients with sev ere illness
have developed extrathoracic pathology that involved the kidneys, heart, liver,
spleen and brain. Instances of pyelonephritis, hepatic a b s c e s s e s , cerebral
myoglial reactions, pericarditis and endocarditis have been reported (4, 136).
Degenerative c h a n g e s have been found in th e se organs, but m acroscopic
lesions are uncommon.
Unusual complications such a s dual infection with multiple sp ecies (26)
or subtypes (78) of Legionella or other opportunistic p athogens have been
reported. In addition, serologic confirmation of sub-clinical infection and diverse
clinical presentation of d ise a se following repeated exposure to the sam e source
of L. pneumophila h as been described (58, 136).
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1.4.4

Pathogenesis. L. pneum ophila is a facultative intracellular pathogen

which replicates within alveolar m acrophages of the lung. During the course of
infection, the bacteria are actively phagocytosed by host cells and en ter
p hag o so m es asso ciated with ribosomes and mitochondria. Phagocytosis of L
pneum ophila by m acro ph ages is independent of, but en h a n c e d by, the
p re se n c e of opsonizing antibody and complement. However, phagocytosis by
PMNLs requires th e presence of antibody, is not bactericidal and d o e s not
support the growth of L. pneumophila. Direct penetration of bacteria into
eukaryotic cells h a s been su g g ested but uptake of L. pneumophila by guinea
pig m acro ph ages h a s been show n to occur by a conventional phagocytic
p ro cess (36).
Studies have shown that m acrophages exhibited an oxidative burst upon
internalization of virulent L. pneumoohila but su b seq uen t events such a s
phagolysosomal fusion and acidification of th e ph ag osom e were inhibited (71,
73). Rapid intracellular multiplication of L. pneumoohila w as followed by
cellular lysis with re le a se of organism s and continued s p re a d to ad jacen t host
cells. Further s p re a d of the organism via the bloodstream has been described
and m ay explain th e extrapulmonary pathology observed during a d v an ced
stag e s of the d is e a s e process (31, 105,136).
Although no single microbial feature h a s been show n to confer virulence
on L. pneumophila , a number of bacterial products have been implicated as
potential factors which contribute to its pathogenicity. R elea se of toxins which
neutralize the bactericidal pathw ays of phagocytes (50) a n d induce necrotizing
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inflammatory and cytolytic resp o n ses in human tissues (6, 10) may be the most
important pathogenic asp ects of the legionellae.
1.4.5

Diagnosis. Difficulties involved in the diagnosis of L. pneum ophila

infections are due primarily to the similarity between sym ptom s of Legionella
infections with those of other bacterial and viral pneum onias and the nonpathognomic radiographic ap p earan ce of the disease. In addition, failure to
stain the organism in clinical sam ples further complicates positive identification
of legionellae a s the causative agent.

T hese problems m ake it n ecessary to

rely on culture, serology, and detection of bacterial nucleic acid or antigen as
the main m ethods for the diagnosis of Legionnaires' d isea se.

Table 1.6

illustrates clinical an d laboratory diagnostic indicators of legionellosis.
The mainstay of laboratory diagnosis remains culture on selective
bacteriological media {31, 137). Growth on BCYEa with supplem ented Lcysteine in the a b s e n c e of growth on a blood ag a r media is indicative of JL
pneum ophila. Recovery of clinical specim ens by culture will identify 50 to 80%
of positive sam ples a n d this has b een reported to have a specificity of 100%
(137). Colonial morphology is distinct and requires two to five days for positive
identification. Once isolated, confirmation of th e se tests should be m ad e by a
gram stain in which carbol fucshin is substituted for safranin a s the counter-stain
along with immunofluorescence. Figure 1.3 illustrates the rationale for
determining the laboratory detection of L. pneumophila.
The developm ent of a variety of serological tests including indirect
immunofluorescence a s s a y s (IFA) h a s been useful in the identification of
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Table 1.6

D iagnosis of Legionnaires' D ise a se

Clinical diagnosis
O nset
fever
rigors
headaches
w eakness
gastrointestinal abnormalities
Acute p h a s e
unremitting fever
radiographic abnormalities
non-productive cough
nervous system manifestations
dyspnea
Laboratory diagnosis
O rganism detection methods (culture, immunofluorescence, nucleic acid
probes, etc.)
Slightly elevated white blood cell count
hyponatrem ia
proteinuria
hem aturia
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Identification S c h e m e for L. p n e u m o p h ila

Growth on B C Y E a of gram-negatiYe bacillus
N o __________________ 1_____________________ Yes
I
I
Not L. pneum o ph ila
Potential L. pneum ophila
I----------------------------

1

Growth on B C Y E a without L-cysteine
at 37 ° C in 3 days
Y e s _____________ J_______________ No
I
I
Probably not L. pneum ophila
Possible L. pneum ophila
I
Growth o n blood containing a g a r
I
Not L. pneum ophila
Immunofluorescence or Agglutination
P o sitiv e ----------------1---------------- Negative
Presum ptive L. pneum ophila

Probable L. pn eum ophila

B ioc hem icaIA na lysis for co nfirmation

Figure 1.3. Flow s c h e m e for the identification of L. pneum ophila.
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Legionella antibody for diagnostic purposes. Although, IFA h as a sensitivity of
approximately 75% and a specificity of almost 100%, problems have arisen in
its use for diagnosis of sporadic c a s e s of Legionnaires' d isease. This is d u e to
the incidence of cross-reactivity reported with the use of L. pneumoohila
antibody and the inherent difficulty involved in the subjective interpretation of
the assay. Detection of seroconversion to a four-fold titer by serological
m ethods is useful, but yields retrospective results and should be interpreted
with caution (4, 64, 137).
Direct observation of L. pneumophila antigen in clinical specim ens by
IFA has provided relatively rapid diagnoses but with low sensitivity. Problems
d u e to reagent cross-reactivity with other bacteria and the environmental
p resen ce of th e legionellae have lead to false-positive results (4, 64).
Commercial nucleic acid probes are now available and exhibit better sensitivity
th an IFA, and although they are gaining widespread acceptan ce, further
examination is n eeded before they replace IFA completely.
Radioim m unoassay, latex agglutination, microagglutination, counter immunoelectrophoresis, hemagglutination and enzym e im m unoassay techniques have
b een used or are currently being investigated for application a s rapid, sensitive
an d specific diagnostic tools (64, 114).
1.4.6 Immunity.

The immune respo nse to Legionnaires' d is e a s e is not well

understood. However, epidemiological evidence h a s su g g e ste d that
susceptibility an d resistance to Legionella infection are directly related to risk
factors which usually immunocompromise the host. Advanced ag e, underlying
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disease, excessiv e cigarette smoking and im munosuppressive therapy have
been shown to influence attack and fatality rates of Legionnaires' disease.
Experimental studies have dem onstrated that the cellular arm of the immune
system may have a significant role in resistance to infection with L.
pneum ophila. Freidman et al. (51) dem onstrated that lymphokine activated
m acrophages did not support the growth of ingested legionellae while Horwitz
et al. (72) sh ow ed that non-specific activation of th e s e cells also inhibited
intracellular replication of Legionella. That untreated alveolar m acro ph ag es of
mice did not support intracellular growth of this organism (140) further
su g g ested that a sp e c ts of the bacteria-m acrophage interaction have a central
function in the immune resp o n se to legionellosis.
The role of humoral immunity h a s not been well-defined. Theoretically,
th e introduction of anti-L. pneumophila antibodies would facilitate opsonization
of bacteria with detrimental results to the host. However, animal studies have
dem onstrated that passive transfer of antibody against L. pneumophila is
effective again st su bsequ ent challenge with whole organism s (104, 136).
It has b e e n difficult to establish whether individuals who h av e contracted
legionellosis a r e susceptible to re-infection. R esearchers have shown that
immunization of guinea pigs with killed antigen is protective in s o m e cases, but
not in others (7, 33). Winn and Davis (136) were able to protect guinea pigs for
o n e month after infection by aerosol or intratracheal route with a sub-lethal
inoculum of L. pneum ophila.
Human d e fe n se s against legionellosis most likely involve synergistic
action of the cellular and humoral immune system. Studies that have elucidated a
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defense system in animals have dem onstrated limited bacterial Killing or
bacteriostasis of L. pneumophila. Further work is needed to fully delineate the
m echanism s of hum an resistance to Legionnaires’ d isea se.
1.4.7

Antimicrobial Therapy.

Erythromycin is the current clinical drug of

choice for legionellosis. Studies have shown that the clinical reaction to this
antibiotic may range from an immediate resp on se to no therapeutic results at all.
Relapse of infection an d development of sev ere phlebitis with intravenous use of
erythromycin have b een reported (62). Rifampicin is generally considered the
most effective drug in vitro and h a s been u sed effectively in combined clinical
therapy with erythromycin, but can not be used alone due to the high frequency
with which bacterial resistance is induced. Consequently, alternative antimicrobial
therapeutic regimens are being sought for the treatment of clinical legionellosis.
L. pneumophila is sensitive to a wide variety of antibiotics in vitro (30, 60,
123). However, th e se sensitivity levels are not always reflected in clinical trials.
Antimicrobial agents with an effective minimum inhibitory concentration (MIC) such
a s the am inoglycosides, cephalosporins and penicillins a re reported a s ineffective
in the treatm ent of hum an Legionnaires' d ise a se (82) while others such a s
erythromycin, rifampicin and the tetracyclines have an effective role in therapy (2).
Discrepancy between experimental and clinical trials may b e explained by the
inability of various antibiotics to penetrate host cell m em b ran es and reach
intracellular bacteria. Indeed, it h a s been reported that ciprofloxacin, erythromycin
and rifampicin (65, 130) inhibit intracellular growth of L. oneumoohila in cell
cultures, while the p-lactam antibiotics such a s ampicillin, cefoxitin and cefotaxime
do not (142).
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Of the new antibiotics examined, the quinolones have shown great promise
in vitro an d in animal studies (44, 45, 60, 128, 129). Ciprofloxacin, the best
studied compound of this group, is a broad spectrum antibiotic which offers
exceptional oral bioavailability and achieves high tissue concentrations. It is welltolerated by patients and has b een used successfully in the clinical treatment of
various urinary and respiratory tract infections. Results from animal studies
indicated that the efficacy of ciprofloxacin is equal to or g reater than that of
erythromycin and rifampicin in treatment of experimental Legionella infections (44,
4 5 ,1 2 8 , 129). Further studies are in progress to develop practical in vivo
screening methods for the evaluation of new antimicrobial a g e n ts for treatm ent of
clinical Legionnaires' d isease.
Despite the m assive accumulation of d a ta concerning the nature of L.
p neum ophila since its initial isolation and identification following the epidemic in
Philadelphia, Legionnaires' d is e a s e remains a major c a u s e of pneum onia in
humans. Enhanced aw aren ess of this syndrome and aggressive therapeutic
regim ens have helped in the maintenance and treatment of legionellosis, but
further stud ies are n e e d e d to establish prophylactic or preventative m e a s u re s
especially for "at risk groups". Elucidation of th e pathogenic m echanism s of the
organism an d the role chem otherapeutic ag en ts play in the treatm ent of d isea se
a s well a s the investigation of the mechanisms of attachment and penetration used
by I., pneumophila to initiate the d isea se process may lead to new developm ents
in the control of this important hum an disease.
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S e c tio n II

2.

H ypothesis and Specific aim s.
L. pneumophila is the causative agent of a fatal form of pneum onia

known a s Legionnaires' disease. T he organism is a facultative intracellular
pathogen which a tta c h e s to, pen etrates and replicates within alveolar
m acro ph ages of the lung. Continued growth and s p re a d of L. pneumophila
leads to the presentation of well-defined clinical features a s well a s to extensive
pulmonary and extrapulmonary pathology. The m echanism s by which L
pneum ophila recognizes and attach es to host cells are crucial to the initiation of
d ise a se in a susceptible host. The p ro cess of binding w as investigated using
human cells in culture in order to elucidate these earliest s ta g e s of microbial
infection. It is postulated that determination of th e s e ad h eren ce events will lead
to better understanding of the nature of this infectious d isea se an d to the
developm ent of more effective control measures. Of the present therapeutic
regimens, erythromycin is the preferred drug for treatm ent of Legionnaires'
d isease. However, patients in the advanced s ta g e s of severe illness often
respond poorly to such antimicrobial treatment. The in vitro activity of
established antibiotics along with novel, potentially useful drugs were evaluated
against the organism per s e to define the kinetics a n d mode of action of th e se
antimicrobial agents. Furthermore, t h e in vivo p ath o g en esis an d pathology
induced in experimental L. pneumophila infection in the chick embryo were

35

examined and the ability of clinically proven or potentially useful antibiotics to
control or ameliorate the d isea se p rocess was investigated in this animal
system. From the results of th ese combined studies it is anticipated that novel
preventative or control m easures may be forthcoming for the treatment of
Legionnaires' d isea se.
Specific aims of this project w ere:
1) to establish the experimental param eters leading to the characterization of
Legionella pneum ophila adherence factors by using the hum an cell lines U937
(macrophage-like) and MRC-5 (lung fibroblast) to partially define these
ad h esin s;
2) to elucidate the in vitro activity of selected antibiotics on the growth and
morphology of Legionella pneum ophila:
3) to delineate the cellular and sub-cellular pathology induced in the chick
embryo following experimental infection with Legionella pneumophila and to
define the path og en esis of infection in this system;
4) to examine th e role of antimicrobial agents in the disease a n d recovery
p ro c e sse s.
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S ection III

Partial Characterization of Legionella pneum ophila
Adherence to Host Cells

3.1

Abstract
The m echanism s by which the facultative intracellular pathogen,

Legionella pneum ophila, attached to macrophage-like (U937) and human
embryo lung (MRC-5) cells in vitro was examined. Bacteria and host cell
surfaces were modified or treated with degradative enzym es, detergents,
fixatives, lectins, oxidizing chemicals, and sugars prior to adherence a s s a y s in
order to elucidate putative bacterial adhesins and eukaryotic receptors
responsible for mediating specific bacterial binding to th e se cell lines. Bacterial
attachm ent to host cells was determined by viable count and indirect
imm unofluorescence assay methods. Results from th e se studies su g g ested
that one or more lectin-like structures on the surface of L. pneumophila
organism s may potentiate the specific recognition of eukaryotic host cells.
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3.2

Introduction
The specific recognition of host cells by pathogenic bacteria forms a

n ecessary prelude to the initial stages of the d isea se state (8 ). Duguid (28) first
coined the term "adhesin" in 1959 to describe the adhesive structures on
bacteria which facilitate their ability to attach to susceptible eukaryotic cells. This
work remained largely unnoticed until Gibbons (56) reported on the adherence
of bacteria to specific a re a s of the oral cavity. Since that time, num erous and
extensive investigations (9, 25, 39, 41, 92, 93, 95, 96, 97, 98, 100, 117, 119,
1 2 0 , 126, 131, 132) concerning the interaction of pathogenic organism s such a s

Escherichia coli. Neisseria g o n o rrh o eae. Vibrio cholerae and S treptococcus
p y o g e n e s with host cells have increased our understanding of how bacteria
initiate disease. T h e se reports described experiments in which th e in situ
blocking, inhibition or enzym e degradation of putative bacterial a d h e s m s and
eukaryotic receptors were designed to identify these structures and characterize
the nature of microbial adherence to host cell surfaces.

Further studies

demonstrating the inhibition of binding by these isolated bacterial
co m p o n en ts/ad h esin s or by adhesin/receptor specific antibody provided
additional evidence that th e s e molecules w ere responsible for bacterial
attachment. Although a num ber of th ese structures have been implicated by
th e s e methods, pili are the best studied (98, 119) and have been shown for a
num ber of bacterial species to act sequentially or concomitantly with other
attachm ent factors (39, 131) during the binding process.
The elucidation of ad h esin s and their receptors h a s led to the
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development of novel strategies for the prevention and control of infectious
d isea ses. Prophylactic or post-infection treatment with anti-adherence vaccines
and purified adhesin/receptor or adhesin/receptor an alo g u es u sed in a
competitive fashion have yielded encouraging clinical results (8 ). In addition,
studies have indicated that sublethal d o ses of antibiotics may alter the ability of
som e bacteria to ad h ere to host cell surfaces (22 ).
L. pneumophila is a facultative intracellular p athogen which replicates
within alveolar m acrophages in clinical d ise a se but h as been shown to multiply
within a wide variety of eukaryotic cells in vitro (36, 74, 75, 91, 138). The
preliminary steps involved in the attachment of this organism to potential host
cells prior to invasion have not been elucidated. However, L pneumophila has
been show n to p o s s e s s pili, fimbriae and flagella (108, 11 0 ) on their surface
and th e se , a s pointed out by Rodgers (106) and Figure 3.1, may potentiate
binding by bridging the gap between the negatively ch arged surfaces of the
invading pathogen an d host target cells.
Oldham and Rodgers (91) studied the interaction of L. pneum ophila with
MRC-5 cells, a hum an embryonic lung cell line, both quantitatively (viable
counts following eukaryotic cell lysis) as well a s qualitatively (by electron
microscopy). Attachment of the legionellae to cells w as followed by a
thickening of eukaryotic cell m em branes and the proliferation of microvilli which
led to bacterial endocytosis by a process which they term ed "bacteriopexis".
More recently, Cianciotto et al. (23, 37) u sed U937 cells, a macrophage-like,
human histiocytic lymphoma cell line, a s a cellular model of infection and
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su gg ested that a 24-kDa surface protein of L. pneumophila potentiated
infectivity and su b seq u en t intracellular replication. In addition, b e c a u s e similar
results with explanted human alveolar m acrophages were obtained, th ese
investigators have dem onstrated the relevance of this transform ed cell line in
the study of L. pneumophila pathogenesis in vitro.
Patients with systemic Legionnaires' d is e a s e often respond poorly to
antibiotic therapy. Vaccines prepared to stimulate antibody production against
whole L. pneumophila organisms lead to avid opsonophagocytosis by the
"preferred" host cells (macrophages) and may prove counterproductive to
therapy. The objective of this study was to conduct preliminary studies on the
attachm ent of L pneumophila to U937 and MRC-5 cells a s a prerequisite to
infection at the cellular level. Specific goals included the developm ent and
establishm ent of the experimental param eters for adh eren ce a s sa y s a s well as
the partial characterization of bacterial "adhesins" and eukaryotic receptors
involved in the "recognition" process. Fixatives, lectins, detergents, oxidizing
chemicals, degradative enzym es and sugars w ere used to modify either
bacterial or eukaryotic cell surfaces. Following these treatments, L,
pneum ophila w as a d d e d to the te st cells and adherence a s s a y experiments
performed. Viable counts of organisms (following eukaryotic cell lysis) and
immunofluorescence a s sa y s (IFA) (for direct counts of labelled bacteria) were
done an d the number of bound organisms following ad h eren ce w as
determined. Percent inhibition of binding w as ascertained by direct comparison
of results from treated and untreated control trials.
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Due to the complexity of the bacterial an d host-cell m em branes, d a ta
derived from studies of this nature are often hard to interpret an d the
experimental procedures often lead to contradictory results making definitive
adherence criteria difficult to elucidate (8 , 70, 120).

For th e s e reasons,

research ers have b a s e d their conclusions upon well-controlled, stringently
analyzed experiments. It has been generally accepted that only those
experimental treatm ents that inhibited bacterial adherence at a level equal to or
greater than 50% of untreated controls were significant. In the present study,
similar inhibition levels were used to m easure the experimental significance of
treatm ents for the binding of L. pneum ophila to U937 or MRC-5 cells. In
addition, b e c a u s e quantitative m easu rem en ts of bacteria binding are often
difficult to a s s e s s accurately, two different types of a s sa y m ethods were used,
and the results cross-referenced, to evaulate bacterial binding to host cells.
T he identification of the factors that lead to bacterial ad h eren ce will help
characterize the initial stag e s of bacterial invasion of host cells and increase our
understanding of the pathogenic properties of L. pneum ophila. The results from
these studies may su g g e st potential clinical regimens for blocking infection at
the cellular level or the development of split vaccines leading to novel
ap p ro ach es in the prevention and control of Legionnaires' d ise a se .
3.3

Materials and Methods
R eagent formulations and preparations along with detailed procedures

are given in Appendices 1 and 4.
Bacterial strain and cultivation. L. pneum ophila serogroup 1, strain
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Nottingham N 7, was isolated from the sputum sample of a fatal ca se of
Legionnaires' disease, subsequently p a s s a g e d on bacteriological media, and
maintained fully virulent in a frozen state in serum sorbitol at -70° C. Cultures
w ere grown on buffered charcoal yeast extract agar supplem ented with aketoglutarate (BCYEa) (29) a s previously described {128, 129) at 37°C for 48 h.
To ensure the u se of a consistent population of organism s in all experiments, L
pneumophila w ere harvested from plates, inoculated into buffered yeast extract
broth supplem ented with a*ketoglutarate (BYEa broth) (112) to give a initial
concentration of approximately 1os organisms/ml and incubated in a shaking
w ater bath for 24 h at 37oC until the culture had reached approximately 2-3 x
108 colony forming units (cfu)/ml a s determined by s u b se q u e n t viable counts.
Bacteria were harvested by centrifugation at 3000 x g in a Beckman Microfuge
12 (Beckman Instruments, Palo Alto, Ca.). This procedure did not alter either

the ability of organism s to adhere to eukaryotic cells or influence the LD50 for
th e fertile h en 's egg (see Section 5). Organism s were w a s h e d in Hank’s
B alanced Salt Solution (HBSS) (Irvine Scientific, Santa Ana, Ca.) and diluted
1 :10 in HBSS prior to ad h eren ce assays. The ratio of bacteria to cells w as

approximately 100:1 for both cell lines u sed in these trials. The rationale for the
selection of this multiplicity of infection (MOI) a s the inoculum for both cell lines
w a s based on d a ta derived from a) bacterial adherence experiments (see
A dherence to U937 and MRC-5 cells, p. 44) an d b) a d h e re n c e studies on other
microorganisms in which an inocula of 100 MOI was used.
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E u k a ry o tic cells a n d gro w th c o n d itio n s . U937 cells. U937 cells,
derived from a histiocytic lymphoma cell-line, were obtained from the ATCC
(Rockville, Md.) and maintained a s replicative, non-adherent monocyte-like
cells in Minimal Essential Medium with Earle's salts (MEM) (Irvine Scientific,
S an ta Ana, Ca.) supplem ented with 10% bovine calf serum (Hyclone
Laboratories, Inc., Logan, Utah) and 3mM L-glutamine (Sigma Chemicals, St.
Louis, Mo.). The cells were grown in T-75 cm 2 flasks (Costar, Cambridge, Ma.)
and harvested for use in ad h e re n c e trials at points when th e culture reached
late exponential phase of growth (1-2 x 10 6 cells/ml). At this stage, th e cells
were differentiated into a non-replicative, adherent macrophage-like cell line
with 12-O-tetra decanoylphorbol-13-acetate (TPA) (Sigma Chemicals, St. Louis,
Mo.), which w as added at a final concentration of 10-0 M for 48 h. Cells were
removed from flasks with 0.2% EDTA, w ash ed with media, and distributed into
24-well plastic plates (Costar, Cambridge, Ma.) at a cell density of 4-8 x 105
cells/well for u s e in viable count adherence a s s a y s or into similar 6 -well plates
containing g lass coverslips at a cell density of 5-8 x 105 cells/well for u s e in IFA
counts.
MRC-5 cells . MRC-5 cells, a semi-continuous, adherent line of human
embryonic lung fibroblasts, w ere obtained from Flow Laboraties (McLean, Va.)
and maintained in MEM supplem ented with 10% bovine calf serum an d 3 mM Lglutamine. Cells were grown to a confluent state in 24-well or 6 -well plates (on
g lass coverslips) and u sed directly for viable count or IFA L. pneumophila
ad h eren ce a s s a y s . Confluent cell monolayers reached a density of
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approximately 1-2 x 10 5 cells/well in 24 well plates a n d approximately 2-3 x 10 5
cells/coverslip in 6 well plates.
Adherence to U937 and MRC-5 cells. To determine th e maximum
bacterial binding capacity to both cell ty p es in these a s s a y s , L. pneumophila
w as grown in BYEa broth for 24 h as described. Cultures were pooled,
centrifuged, serially diluted ten-fold and e a c h dilution a d d e d to 6 a n d 24-well
plates containing either U937 or MRC-5 cells for 1 h. T h e number of organisms
bound to each cell type w as assay ed by viable count a n d IFA m ethods to
determ ine the specificity of bacterial attachment to th e s e cells.
Inhibition of adherence. Bacterial tre atm e n ts. The role of L,
pneum ophila surface proteins and sugar moieties in th e ad h eren ce process
w a s examined. L. pneumophila was treated with degradative enzym es,
detergents, fixative and oxidizing chem icals and ad h e re n c e determ ined by the
viable count and IFA m ethods described below {p. 45-47). The type, treatment
time, concentrations and m ode of action of the agents u s e d to modify the
surface of the bacteria are shown in Table 3.1. All ag en ts, with the exception of
glutaraldehyde (Electron Microscopy Sciences, Ft. Washington, Pa.), were
obtained from Sigm a Chemicals (St. Louis, Mo.) and prepared at th e
concentration specified in HBSS prior to testing. Bacteria were tre ated with the
test agent for the time indicated, w ashed th ree times in HBSS and u s e d in the
ad h eren ce a s s a y s (p. 45)
Eukaryotic treatm ents. The role of eukaryotic surface protein,
glycoprotein, lipid, glycolipid or sugar w a s examined a s possible ad h esin s in
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the binding process. The type, treatment time, concentrations, and m ode of
action of the degradative enzym es, detergents, fixatives, oxidizing chemicals
and lectins u sed to modify the surfaces of U-937 and MRC-5 cells are shown in
Table 3.2. All ag en ts were obtained from Sigma Chemicals (St. Louis, Mo.) with
the exception of the glutaraldehyde and formaldehyde (Electron Microscopy
Sciences, Ft. Washington, Pa.) and prepared at the specified concentration in
HBSS prior to testing. Cells were treated with ag ents for the time indicated and
w ash ed three times with HBSS prior to ad h eren ce assay s.
S u g a r s . A num ber of sugars were examined a s possible inhibitors of the
attachm ent pro cess by conducting adherence a s s a y s in the p resence of these
carbohydrates. M onosaccharides (Sigma Chemicals, St. Louis, Mo.) u se d in
th e s e studies are shown in Table 3.3. Sugars were prepared at the specified
concentrations in HBSS, adjusted to pH 7.2 and added to cells 10 minutes prior
to the addition of L. pneumophila for adherence experiments.
Adherence assays. U937 and MRC-5 cells were w ash ed th ree times
with HBSS prior to adherence experiments. Following either treatm ent of
bacteria and/or eukaryotic cells with the agen ts to be tested or after competitive
binding, cells w ere w ash ed with HBSS and L pneumophila added to wells of 6
and 24-well plates and allowed to adhere to eukaryotic cells for 1 h.
Appropriate control organisms and cells were treated with HBSS. After the
binding period, unattached organism s were removed by three-fold w ashings
with HBSS and host-cell bound organisms a s s a y e d by viable count an d IFA
m ethods a s follows:
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Viable co u n ts. After removal of non-adherent L. pneumophila eukaryotic
cells were lysed by the addition of 1 ml of sterile distilled water.

This procedure

did not affect the viability of the bacteria a s ascertained by viable count studies
of similarly treated organisms. Bacterial counts were m a d e on lysates from
each of 10 sep arate wells by inoculating 10 fil in duplicate of appropriate
dilutions onto BCYEa plates. Plates containing 30 to 300 colonies after an
incubation period of 72 h were used to calculate av erag e viable counts of
lysates for each well a s previously described (91). Ratios of cfu/eukaryotic cell
w ere determ ined by dividing average lysate values for e a c h well by the number
of eukaryotic cells s e e d e d per well. T h ese values were com pared to untreated
control values within each experiment for determination of the percent reduction
of ad h e re n c e following each treatment used.
Non-specific binding of organisms to the plastic culture plates w as
determ ined for each experimental trial. For every well, viable count estimations
of unbound organism s contained in w ash es made following the 1 h incubation
period for a d h eren ce a s s a y s were determined. This value w as a d d e d to the
corresponding lysate value for the appropriate well and subtracted from the
inoculum. The resultant figure w as used to estimate the presence of bacteria
non-specifically stuck to exposed plastic not covered by the cell monolayers. In
multiple experiments, this value was found to be a consistently small
percentage of the inoculum. The level of nonspecific binding was found to be
unaffected by bacterial or eukaryotic cell treatments and w a s not altered by the
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addition of de-ionized water.

Im m unofluorescence. Following bacterial or eukaryotic cell treatments
and binding experiments, U937 and MRC-5 cells were fixed in 10% buffered
formalin for 12 h, w ashed in HBSS, an d treated in situ on the glass coverslips
with a 1:100 dilution of rabbit anti-L. pneumophila antibody (see Appendix 4) for
1 h at 3 7 o C. Unbound globulin w as removed with three-fold washings of

HBSS. Cells w ere then treated with a 1 :200 dilution of goat anti-rabbit FITC
conjugated antibody (Cooper Biomedical, Malvern, Pa.) for 1 h at 37° C.
Unbound globulin w as removed by repeated w ashings and cells
counterstained with 1% (w/) propidium iodide for 5 min.

G lass coverslips were

mounted in 1% (w/v) 1 ,4- diazobicyclo (2.2.2.) octane (DABCO) (Sigma
Chemicals, St. Louis, Mo.) in glycerin onto microscope slides and viewed with
an Olympus BH-2 epifluorescence microscope using an excitation filter emitting
a wavelength of 490 nm and a barrier filter blocking w avelengths above 515
nm. The num ber of fluorescing organism s bound to 200 eukaryotic cells w as
determ ined and ex p ressed a s adherent organisms/cell. T h e se w ere com pared
to control values within each experiment to determine the percent reduction of
ad heren ce. Non-specific binding of labelled organisms to a r e a s of g la ss not
covered by eukaryotic cells w as ascertained by IFA. Although this w as noted to
be insignificant in all experiments, th e se organism s were not counted in the IFA
a s s a y for a d h eren ce to host cells.
3.4 Results
Adherence to U937 and MRC-5.
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Bacterial binding to U937 an d

MRC-5 cells is illustrated by IFA in plate 3.1 and binding curves for both cell
lines are summ arized in Figures 3.2-3.5. For each cell type, the use of
approximately 5 x 108 cfu/ml a s the inoculum gave a d h e re n c e kinetics
approaching saturation of the eukaryotic receptors. This w as consistent for
either U937 (Figures 3.2 and 3.3) or MRC-5 (Figures 3.4 and 3.5) cells a s
determined by both a s s a y techniques. The saturation points corresponded to
an average cfu/cell ratio of 2.5 and 11 1or U-937 (Figure 3.2) and MRC-5 (Figure
3.4) cells, respectively, a s assay ed by viable counts. IFA equivalent ratios were
3.1 and 6.9 organisms/cell for U937 (Figure 3.3) and MRC-5 (Figure 3.5) cells,
respectively. At this high inoculum level, marked non-specific binding to the
plastic of culture dishes and glass coverslips were noted by both viable counts
a n d IFA. However, the u se of an inoculum with 10-fold fewer organism s
(approximately 5 x 107 cfu/ml) gave non-specific binding levels that were
dramatically reduced. This inoculum was equivalent to about 100 bacteria/
eukaryotic cell (or 100 MOI) and approached the saturation point of eukaryotic
receptors of both cell lines.
Inhibition of adherence studies. Bacterial tre a tm e n ts . Figures 3.63.9 illustrate th e percent reduction of adherence following modification of L
pneum ophila with the agents listed in Table 3,1. Prior treatm ent of L.
pneum ophila with glutaraldehyde, p-galactosidase, chymotrypsin, lipase,
protease, trypsin and sodium metaperiodate all effected a greater than 50%
reduction in a d h eren ce to U937 cells a s com pared with controls in both viable
count and immunofluorescence assay s. For MRC-5 cells only bacterial
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treatm ents with glutaraldehyde, chymotrypsin, protease, trypsin and sodium
m etaperiodate effected a similar response; i.e., unlike for U937 cells, lipase and
(3-galactosidase treatment did not significantly influence bacterial binding to
MRC-5 cells. Bacterial ad h eren ce or inhibition of binding to both U937 and
MRC-5 cells w as consistently similar whether a s s a y e d by viable count or IFA
methods.
Eukaryotic treatm ent. Figures 3.10-3.13 illustrate the percent reduction in
ad h eren ce following modification of U937 and MRC-5 cell surfaces with the
ag e n ts listed in Table 3.2.

Concanavalin A, wheat germ agglutinin, sodium

m etaperiodate, nonidet P40, glutaraldehyde and formaldehyde reduced
binding of L .pneum ophila to treated U937 cells by greater than 50% (Figures
3.10 and 3.11). Similar results were obtained by viable count and IFA
g en erated data. It was noted that none of the enzymatic treatm ents reduced
bacterial binding to U937 cells. In addition, modification of U937 cell surfaces
with cytochalasin B, a eukaryotic microtubule formation inhibitor, did not result
in differences betw een treated and untreated cells a s m easured by either a s s a y
technique. T h e se results were difficult to interpret but sug gested that bacterial
uptake by the phagocytic U937 cells may be independent of attachm ent since
the difference between the two assay s w as not great.
The percent reduction of adherence to MRC-5 cells following treatment
with the modifiers listed in Table 3.2 are illustrated in Figure 3.12 and 3.13.
Concanavalin A, wheat germ agglutinin, sodium m etaperiodate, nonidet P40,
glutaraldehyde an d formaldehyde effected significant reductions in bacterial
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binding a s m easured by viable counts and IFA. However, viable counts but not
IFA indicated that lipase and chymotrypsin treatment of cells reduced
ad h e re n c e by greater than 50%.
In all eukaryotic treatm ents with either cell line a s s a y e d by both
techniques, concanavalin A, w heat germ agglutinin, glutaraldehyde and
formaldehyde were the strongest inhibitors of bacterial binding.
S u g a r s . Co-incubation of L pneumophila with either cell line in the
p re se n c e of those su g a rs listed in Table 3.3 are illustrated in Figures 3.14-3.17.
Of th o se tested, no m onosaccharide was able to significantly reduce bacterial
binding to U937 or MRC-5 host cells. Viable count and IFA techniques yielded
similar results for ail sugars tested.
3.5 Discussion.
T h e adheren ce of microorganisms to host cells a s a prelude to the
d ise a se p rocess h a s been well docum ented (8 ). A num ber of bacterial
com ponents, including pili and fimbriae, have been shown to mediate the
specific attachm ent of microbes to eukaryotic cells (8 , 70, 116), but evidence
has su g g e ste d that th e s e and other structures may act concomitantly or
sequentially (39, 131) in this process. In addition, the role of van der Waals,
thermodynamic forces and hydrophobic interactions in th e initial attachm ent
and eventual binding of bacteria to cell surfaces is still unclear. The param eters
for both an effective bacterial binding assay and a rationale for determining
ad h eren ce were established. T h e se criteria were used to partially characterize
the nature of "adhesins" involved in L. pneumophila adh eren ce.
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The adherence curves indicated that a specific interaction betw een L.
pneum ophila and both cell types occurred. Bacterial binding to eukaryotic
receptors approached apparent saturation levels when an inoculum of
approximately 108 cfu/ml was u se d in adheren ce assay s. However, this d ata
required caution in interpretation a s increasing quantities of non-specific
binding to plastic wells were noted to exceed acceptable levels at this point.
Determination of adherence a s m easured by viable count and IFA
techniques yielded consistent a n d corroborative results and provided evidence
that a lectin-like adhesin(s) associated with the surface of L. pneumophila was
in part, responsible for mediating attachment to U937 and MRC-5 cells.
Degradation and immobilization of bacterial surface proteins with enzym e and
fixative treatm ents a s well as periodate oxidation of microbial su g ars
significantly reduced L. pneumophila adherence to both types of host cells. That
lipase and (5-galactosidase treatment of bacteria prior to ad h eren ce
experim ents significantly reduced adherence to U937 cells, but not to MRC-5
implied th at lipid and lactose moieties may also be important com ponents in the
bacterial binding pro cess. Several gram-negative bacteria p o s s e s s lectin-like
molecules associated with pili, fimbriae, or flagella which enable them to
adhere to host cell surfaces {8 , 70, 120).

L pneumophila p o s s e s s e s

analogous bacterial ap p e n d a g e s (108 and Figure 3.1) which may facilitate
bacterial binding by similar mechanisms. Isolation of th e se structures in pure
form for u s e a s potential blocking ag en ts in similar ad h eren ce experiments will
further elucidate their role as adhesins.
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Treatm ent of eukaryotic cell surfaces with the lectins concanavalin A and
w heat germ agglutinin substantially reduced bacterial binding a n a corroborated
our results from the bacterial treatment trials. That oxidation of eukaryotic cell
surface su g ars with sodium m etaperiodate inhibited bacterial binding further
supported th e s e findings. However, co-incubation of bacteria and cells in the
presen ce of m annose or N-acetyl glucosamine (sugars specific for
concanavalin A and w heat germ agglutinin) failed to appreciably inhibit
attachment. This may be d ue to the p re se n c e of dissacharides or complex
oligosaccharides on the surfaces of the U937 and MRC-5 cells that contain the
appropriate sub-unit m onosaccharides specific for concanavalin A a n d wheat
germ agglutinin. Therefore, the addition of simple m onosaccharides a s
potential blocking agents in th ese experiments may not be recognized by L.
pneum ophila lectin-like surface molecules and consequently failed to reduce
ad heren ce. U se of dissacharides or oligosaccharides in similar competitive
blocking studies may elucidate putative receptors for L. pneum ophila.
However, determination ot th e nature of th e s e "docking" sites by t h e s e methods
are easily complicated by steric considerations such a s the p re se n c e of
disaccharide su g ar receptors conjugated with proteins, lipids or o th er cell
m em brane moieties. In this study, efforts w ere focused on the bacterial
com ponent of L. pneumophila adherence to host cells.
That fixation of cell surfaces drastically reduced L. pneumophila binding
to U937 and MRC-5 cells while treatment with proteolytic enzym es did not, may
signify a requirement for mobile, complex proteins or glycoproteins to facilitate
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the a d h eren ce of bacteria to these cells. In addition, oxidation of eukaryotic cell
surface su g ars with sodium m etaperiodate actively inhibited bacterial binding, A
possible role for th ese molecules could be selective steric masking or exposure
of receptors specific for ad hesin s on the surface of L. pneumophila. In addition,
treatm ent with nonidet P-40 blocked adh erence of L. pneumophila to both cell
lines w h e re a s similar treatm ent with lipase was generally not effective (reducing
ad h eren ce to MRC-5 cells by 53% a s a ssay ed by viable counts only). These
results su g g ested m em branous lipid moieties a s possible com ponents of
eukaryotic receptors a s well. It was clear from the compiled data that a simple
and uniform receptor system for L. pneumophila may not exist on th e surface of
U937 a n d MRC-5 cells. Indeed, synergistic, sequential, steric and hydrophobic
interactions between different m em brane com ponents of host cells may have a
role in th e recognition p ro cess and further complicate the elucidation of host cell
receptors specific for L. pneumophila.
T he cytochalasins inhibit the internalization p ro c e ss e s of eukaryotic cells
and have b een used to determine whether pathogens enter host cells by means
of active invasion or phagocytosis. Elliott and Winn (36) have shown that L.
pneum ophila fails to actively penetrate cytochalasin-treated guinea pig alveolar
m acro p h ag es in vitro. However, the attachm ent of bacteria to phagocyte
m em b ran es w as not inhibited in these trials. In the present studies, adherence
experim ents following treatm ent of the macrophage-like U937 cells with
cytochalasin B resulted in similar binding capacities a s assay ed by viable
counts a n d IFA when com pared to untreated controls. Given that viable counts
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m easure attach ed and internalized organism s while IFA staining facilitate the
detection of only bound bacteria th ese experiments indicate that significant
numbers of legionellae w ere not phagocytosed during the one hour binding
a ssay and that a process of "uptake-independent-adherence" (UIA) occurred for
L. pneum ophila.
Caution should be exercised w hen extrapolating in vitro results derived
from laboratory experimental conditions to the context of the clinical situation.
Neither eukaryotic cell type used in this study were the natural host cell of L.
pneum ophila in human clinical disease. Although both are human cell lines,
U937 cells are macrophage-like cells derived from a histiocytic lymphoma and
may p o s s e s s characteristics not resembling those of primary alveolar
m acrophages. MRC-5 cells are a semi-continuous fibroblast cell from the lung
and exhibit few of the properties of alveolar macrophages. Other potential
factors include environmental differences that exist betw een cells propagated in
vitro as co m p ared with tho se grown in vivo. Exposure to disparate nutritional
sources, regulatory signals and other microorganisms could effect the
expression of host target cell receptors. Similarly, varying nutritional conditions
between th e in vitro and clinical environment will most likely affect the growth of
microorganisms and may alter expression of adhesins responsible for
attachment to eukaryotic cells.
The d a ta from th e se studies offer evidence that a lectin-like adhesin(s)
m ediates attachm ent to U937 and MRC-5 cells. The nature of this receptor(s)
remains to b e elucidated. Host cell receptors most likely consist of
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oligosaccharide and lipid structures that interact to form complex but as yet
unresolved "docking site" for the organism. The finding that lectin-like adhesins
occur on other gram-negative bacteria possessing a p p e n d a g e s such a s pili,
fimbriae, or flagella in association with th ese adhesive molecules suggest that
L. pneumophila may utilize similar attachment strategies. Studies using these
and other fractionated bacterial structures as blocking agents along with wider
c la s s e s of saccharid es in adherence a s s a y s could further characterize or
identify specific com ponents responsible for mediating attachment. The
elucidation of factors which contribute to the binding of L. pneumophila to host
cells will increase our understanding of the pathogenic m echanism s used by
this intracellular pathogen to initiate d ise a se and may eventually influence the
prevention and control of clinical legionellosis.
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Table 3.1.

Bacterial treatm ents prior to adh erence a s s a y s

A gent

C oncentration

Treatment
Time (min)

Enzvm es

Activity
(units/ml)

Treatment
Time {mint

Function

B -galactosidase
chymotrypsin
lipase
n eu ram in id ase
pro te ase
trypsin

100
250
100
20
5
250

60
60
60
60
60
60

Degradation of
protein/sugar-containing
adh esin s on surface of
L. pneumoDhila

Fixative

Treatment

Function

glutaraldehyde

Concentration
Time (min)
0 . 1%

10

Immobilization of protein
moieties

Oxidizina
Aa&oi

Concentration
Time (min)

Treatment

Function

sodium
m etaperiodate

10mM

30

Oxidation of carbohydrate
moieties
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Function

Table 3.2.

Eukaryotic cell treatments prior to adherence a s s a y s
Function

A gent

C oncentration
Time (min)

Treatm ent

Enzvm es

Activitv
(units/ml)

Treatment
Time (min)

Function

Chymotrypsin
Lipase
N euram inidase
P epsin
P ro tea se
Trypsin

0.1
100
1.0
10 0
0.005
50

30
30
30
30
30
30

Degradation of enzyme
sensitive receptors
on host cells

Agent

Concentration
Time (min)

Treatment

Function

Glutaratdehyde
Form aldehyde

0 .1 %
1 .0 %

10
10

Immobilization of proteincontaining moieties

Nonidet P40

0.005%

60

Action on m em brane
lipids

Sodium
m etaperiodate

5mM

10

Oxidation of carbohydrate
moieties

cytochalasin B

3 ug/ml

60

Inhibition of microfilament
formation/phagocytosis

Lectins

Concentration
Time (mint

Treatment

Function

Concanavalin A

1 0 0 ug/ml

60

Binds to m an n o se

Wheat Germ
Agglutinin

1 0 0 ug/ml

60

Binds to N-acetyl
glu co sam in e
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Table 3.3

Competitive binding experim ents

S u g a rs

Concentration

Function

1)
2)
3)
4)

100mM
1 0 0 mM
10 0 mM
10OmM

Competitive
binding

N-acetyl-D-galactosamine
N-acetylneuraminic acid
N-acetylgiucosamine
a-D(-)-Fucose

5) £-D{+)-glucose
6 ) D(+)-mannose
7) D(+)-galactose

100mM
100mM
100mM
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108
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Figure 3.2 Bacterial binding of L. pneumophila to U937 cells a s m easured by
viable counts of organisms released from lysed cells. Ratios of cfu per cell were
calculated by dividing the average lysate value obtained from each inoculum by
the averag e eukaryotic cell s e e d per well. For this experiment the average cell
s e e d equaled 5.7 x 105 cells/well. Bacterial attachm ent to eukaryotic cell
receptors ap pro ach ed saturation when an inoculum of approximately 5 x 10 8
cfu/ml w as a d d ed to cell cultures (arrow). This corresponded to a ratio of 2.5
cfu/eukaryotic cell. Each point represents an average of three separate trials.

60

Inoculum (cfu/ml)

Figure 3.3 Bacterial binding of L. pneumophila to U937 cells a s m easured by
IFA. T he number of fluorescing organism s bound to approximately 200
eukaryotic cells is ex p re sse d as a ratio of organisms/eukaryotic cell for e a c h
inoculum used. An inoculum of about 5 x 108 approached saturation of
eukaryotic receptors (arrow). This corresponded to a ratio of 3.1
organisms/eukaryotic cell.
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Figure 3.4 Bacterial binding of L. pneumophila to MRC-5 cells a s m easured by
viable counts of organisms released from lysed cells. Ratios of cfu per cell were
calculated by dividing the average lysate value obtained from e a c h inoculum by
the average eukaryotic cell s e e d per well. For this experiment the av erag e cell
s e e d equaled 1 .6 X 105 cells/well. Bacterial attachm ent to eukaryotic cell
receptors approached saturation when an inoculum of approximately 5 x 10 8
cfu/ml w as ad d ed to cell cultures (arrow). This corresponded to a ratio of 11
cfu/eukaryotic cell. Each point represents an average of three se p a ra te trials.

62

10
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Figure 3.5 Bacterial binding of L. pneumophila to MRC-5 cells a s m easured by
IFA. The num ber of fluorescing organisms bound to approximately 200
eukaryotic cells is exp ressed a s a ratio of organisms/eukaryotic ceil for each
inoculum used. An inoculum of about 5 x 100 approached saturation of
eukaryotic receptors (arrow). This corresponded to a ratio of 6.9 organisms/cell.
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Agents

B-galactosidase
chymotrypsin
lipase
neuraminidase
protease
trypsin
glutaraldehyde
sodium
metaperiodate

% reduction of adherence

Figure 3.6 Bacterial treatments, U937 cells. Percent reduction of L.
pneum oohila binding to U937 cells a s m easured by viable count estimation of
eukaryotic lysates following treatment of bacteria with th e agents listed in Table
3.1. Each value represen ts the average of 10 separate trials. Error b ars
indicate stan dard error of the mean for e a c h treatment.
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Figure 3.7 Bacterial treatm ents. U937 cells. Percent reduction of L.
pneum ophila binding to U937 cells as m e a su re d by co u n ts of fluorescing
organisms b ou nd to approximately 200 eukaryotic cells following treatm ent of
bacteria with th e agents listed in Table 3.1.
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Agents

B-galactosidase
chymotrypsin

neuraminidase
protease
trypsin
glutaraldehyde
sodium
metaperiodate

% reduction of adherence

Figure 3.8 Bacterial treatments, MRC-5 cells. Percent reduction ol L
pneumophila binding to MRC-5 cells a s m easu red by viable count estimations
of eukaryotic lysates following treatment of bacteria with the ag en ts listed in
Table 3.1. Each value represents the average of 10 se p a ra te trials as
com pared with untreated controls. The standard error of the m ean is indicated
for each treatment.
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Agents
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Figure 3.9 Bacterial treatments, MRC-5 cells. Percent reduction of L,
pneum ophila binding to MRC-5 cells a s m easured by counts of fluorescing
organisms bound to approximately 200 eukaryotic cells following treatm ent of
bacteria with the agen ts listed in Table 3.1.
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Agents

chymotrypsin
lipase
neuraminidase
pepsin
protease ,
trypsin
formaldehyde .
glutaraldehyde _
nonidet P40
sodium '
metaperiodate.
cytochalasin 8
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Figure 3.10 Eukaryotic cell treatments, U937 cells. Percent reduction of L.
pneum ophila binding to U937 cells a s m easured by viable count estimations of
eukaryotic lysates following treatment of host cells with the ag en ts listed in
Table 3.2. Each value represents the average of 10 separate trials. Error bars
indicate standard error of the mean for each treatment.
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Agents

chymotrypsin
lipase
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nonidet P40
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Figure 3.11 Eukaryotic cell treatments, U937 cells. Percent reduction of L,
pneumophila binding to U937 cells a s m easured by counts of fluorescing
organism s bound to approximately 200 eukaryotic cells following treatment of
host ceils with the agents listed in Table 3.2.
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Agents

chymotrypsin
lipase
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Figure 3.12 Eukaryotic cell treatments, MRC-5 cells. Percent reduction of L.
pneumophila binding to MRC-5 cells a s m easured by viable count estimation of
eukaryotic lysates following treatment of host cells with the a g e n ts listed in
Table 3.2. Each value represents the average of 10 sep arate trials. Error bars
indicate the standard error of the mean for each treatment.
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Figure 3.13 Eukaryotic cell treatments, MRC-5 cells. Percent reduction of L
pneumophila binding to MRC-5 cells a s m easured by counts of fluorescing
organism s bound to approximately 20 0 eukaryotic cells following treatment of
host cells with the a g e n ts listed in Table 3.2.
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Sugar
fucose
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glucose
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N -acetyl
galactosamine
N-acetyl
glucosamine
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“ i------------- 1------- 1---------- 1---------- 1-----------1

50

6 0 70

80

90

10 0

% reduction of adherence

Figure 3.14 Competitive binding studies with sugars, U937 ceils. Percent
reduction of bacterial adheren ce following co-incubation of L. pneumophila and
U937 cells in the presen ce of monosaccharide sug ars listed in Table 3.3 as
m easu red by viable counts of eukaryotic lysates. Concentration of added
su gars w as 100 mM. Each value represents the average of 10 sep arate trials.
Standard error of the m ean is indicated for each treatment. None of the sugars
u se d in th ese experiments effected a significant reduction of adherence.
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Figure 3.15 Competitive binding studies with sugars, U937 cells. Percent
reduction of bacterial ad h eren ce following co-incubation of L pneum ophila and
U937 cells in the p resen ce of monosaccharide su g ars listed in Table 3.3 a s
m easured by counts of fluorescing organisms bound to approximately 200
eukaryotic cells. None of the su g ars used in th e se experiments effected a
significant reduction of adherence. Concentration of added su g a rs was 100
mM.
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Figure 3.16 Competitive binding studies with sugars, MRC-5 cells. Percent
reduction of bacterial adh erence following co-incubation of L. pneumophila and
MRC-5 cells in the p resen ce of monosaccharide sugars listed in Table 3.3 a s
m easured by viable counts of eukaryotic lysates. Concentration of added
su g ars w as 100 mM.Each value represents the average of 10 sep arate trials.
Standard error of the m ean is indicated for each treatment. None of the sugars
used in th ese experiments effected a significant reduction of adherence.
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Figure 3.17 Competitive binding studies with sugars, MRC-5 cells. Percent
reduction of bacterial ad h eren ce following co-incubation of L. pneumophila and
MRC-5 cells in the p resen ce of monosaccharide sug ars listed in Table 3.3 as
m easu red by counts of fluorescing organisms bound to approximately 200
eukaryotic cells. Concentration of added sugars was 100 mM.

75

©

Plate 3.1 L. pneumophila binding to U937 and MRC-5 cells in an indirect
immunofluorescence assay. O rganism s are labelled with FITC (green) while
eukaryotic cells are counterstained with propidium iodide (red),
a) L. pneumophila attachm ent to U937 cells. Note incidence of bacterial binding
to host cell surfaces (X 660), b) higher magnification of L. pneumophila binding
to MRC-5 cells. Note single organism attached along its length to the host cell
surface (X 1,650).
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S ectio n IV

The Effect of Antibiotics That Inhibit Cell Wall, Protein and DNA
Synthesis on the Growth and Morphology of
Legionella pneumophila

4.1 Abstract
The response of L. pneumophila to cell wall, protein synthesis and DNA
synthesis inhibitory antibiotics was examined by electron microscopy, MIC
estimations and viable count assays. Cefotaxime, methicillin, rifampicin and
ciprofloxacin, each u sed separately at 20 times their respective MIC values,
showed activity against L. pneumophila in th ese studies. The cell wall
inhibitors, cefotaxime and methicillin, effected the g reatest bactericidal activity
and induced the most extensive morphological ch ang es. Organism s treated
with th e s e antibiotics lost cytoplasmic contents through m em branous lesions
induced in their cell walls. In terms of ultrastructural d am ag e and loss of
viability, th e protein and DNA synthesis inhibitors were less efficacious than
antibiotics that acted on th e microbial cell wall. Rifampicin treated cells
p o s s e s s e d irregular m em bran es and were partially or fully lysed while
ciprofloxacin induced abnormally elongated organisms with intermittently lysed
and d etach ed inner m em branes. T hese results illustrated the ability of clinically
putative antibiotics with diverse modes of action to affect microbial cytology at ■
the ultrastructural level a s well as the viability of L. pneumophila in vitro.
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4.2

Introduction
Leoionella pneum ophila, the causal agent of a fatal form of lobar

pneum onia known a s Legionnaires' d isea se, has been studied by negative
stain, thin-section, freeze-etching, and scanning electron microscopy (105,
108). The response of this human pathogen to treatment with antimicrobial
chem otherapeutic ag en ts has been investigated using various in vitro and in
Yim techniques (19, 30, 35, 44, 45, 57, 60, 65, 83, 107, 109, 112, 128, 129,
142). Although several antibiotics have excellent activity against Li
pneumophila in vitro a s a s s e s s e d in minimum inhibitory concentration (MIC)
studies, few show similar results in clinical trials.
Erythromycin is the current drug of choice for the treatment of
legionellosis; however, inherent problems arise in its use. These include
reports of relapse of infection, onset of phlebitis with intravenous antibiotic
administration an d potential complications associated with the development of
bacterial resistance to therapy.

In addition, studies in which Elliott and Rodgers

(35) examined the morphological and growth response of L. pneumophila to
erythromycin and ampicillin illustrated that erythromycin had limited bactericidal
activity in vitro. Rifampicin has proven effective in clinical trials but is not used
a s the sole therapeutic drug b ecau se of the high frequency with which
resistance is induced. For th e s e reasons, a number of other antimicrobial
agents have been investigated a s potential alternatives for clinical u se in the
treatm ent of legionellosis. Of tho se examined, the quinolone antibiotics have
been the most promising. Ciprofloxacin, the best studied of this group, is a lipid
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soluble antimicrobial which inhibits bacterial DNA gyrase a n d has yielded
encouraging results against experimental L. pneumophila infection in vivo (44,
45, 128, 129).
In the present study, the morphological characteristics and growth
resp on se of L. pneumophila was examined following exposure to antimicrobials
derived from three groups of antibiotics (bacterial cell wall, protein synthesis
and DNA inhibitors). The evaluation of the efficacy of th ese drugs was
determined using MIC estimations, viable count d ata and ultrastructural
investigations.
4.3

Materials and Methods.
R eagent formulations and preparation along with detailed procedures

are given in the appendices 1 and 3 .
Bacterial strain and growth conditions. L. oneum oohila
serogroup 1, strain Nottingham N7 w a s isolated from a sputum sample of a fatal
c a s e of Legionnaires’ disease, was subsequently p a ssa g e d twice on
bacteriological media and maintained fully virulent in a frozen state in serum
sorbitol at -70° C. Cultures were grown on buffered charcoal y east extract agar
supplem ented with a-ketoglutarate (BCYEcc) (29) at 37° C for 48 h. Organisms
w ere harvested from plates and inoculated into a-ketoglutarate enriched
buffered y east extract (BYEa) broth containing 10 g/l yeast extract (Difco), 10g/I
ACES buffer (Sigma), 1 .Og/I a-ketoglutarate (Sigma), 0.4 g/l L-cysteine (Sigma)
and 0.25 g/l ferric pyrophosphate (Sigma). The broth was adjusted to pH 6.9
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with KOH and filter sterilized through a 0.2pm filter to give a final concentration
of approximately 10 5 colony forming units (cfu)/ml. Organisms were incubated
in static culture at 37°C and 5 ml aliquots removed at 4 to 6 h intervals to
develop growth curves for this organism in the broth to be used for subsequent
antibiotic activity studies.
Antibiotics. Dilutions of cefotaxime (sodium salt) (Hoechst-Roussel
Pharmaceuticals), methicillin (sodium salt) (Sigma Chemical Company),
rifampicin (Sigma Chemical Company), and ciprofloxacin (Miles
Pharmaceuticals) were prepared in BYEa broth. Each antibiotic w as added in
the mid-exponential phase of organism growth to give a final concentration of
20 tim es the MIC of each antimicrobial agent. Aliquots of 5 ml were removed
after incubation for 6 and 24 h in the p resence of antibiotics. Organism s were
harvested by centrifugation at 600 g for 10 min, w ashed twice in broth and
either serially diluted for viable counts or prepared for electronmicroscopy.
Control sam ples of untreated organisms were harvested and p repared in the
s a m e manner.
Viable count technique. Bacterial counts were determ ined in
triplicate by inoculating 10 pi aliquots of serially diluted antibiotic-treated
cultures onto BCYEa agar. Resultant cfu/ml were counted from th ose plates
containing 30 to 100 colonies a s previously described (91) to define the
influence of th e s e antibiotics on bacterial viability.
Electron microscopy.

Bacteria were fixed in 3% (v/v) glutaraldehyde
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in 0.05M sodium cacodyiate containing 10mM MgSC>4 (35 ). For negative stain
electron microscopy, 25 pi of each sample w as mixed with an equal volume of
1% (w/v) phosphotungstic acid pH 6.7, and applied to 400 m esh formvar-carbon

coated copper electron microscope grids. For scanning electron microscopy,
sam ples were applied to specimen stubs, dehydrated in a g raded ethanol
series, an d treated with hexamethyldisilaxane (HMDS) (Polysciences, Inc.)
(Warrington, Pa.) (87). Prior to examination, sam ples were coated with 20 nm of
either gold/palladium with a target to specimen distance of 5 cm, at a current of
15 mA for 4 min in a Hummer V sputter coater. For thin-section electron
microscopy, all sam ples were post-fixed in 1 % (w/v) osmium tetroxide,
dehydrated in an ethanol series and em bedded in epon-araldite mixture.
Sections of approximately 60 nm thickness w ere cut on an LKB Ultratome III
with a diamond knife and stained with uranyl acetate 5% (w/v) for 1 min and
lead citrate 0.4% (w/v) for 20 s e c (105, 108).
MIC determination. MICs were determined by the broth dilution
method (133). Briefly, serial two-fold dilutions of each antibiotic were prepared
in BYEa broth and inoculated with cultures in the mid-exponential p h ase of
growth to give a final concentration of 105 cfu/ml. The broths were incubated for
16 h and the lowest concentration of antibiotic which inhibited growth w as taken
a s the MIC (Table 4.1)
4.4

Results.
Viability studies. MIC values for all antibiotics are shown in Table 4.1.
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The growth characteristics and effect on viability of L. pneumophila by the
antibiotics investigated are illustrated in Figures 4.1-4.6 (data on ampicillin and
erythromycin are from reference 35 with permission and are included for a
complete comparative profile).

L. pneumophila grown in BYEa broth, had a

m ean generation time of 1.5 h. The bacterial cell wall inhibitors, cefotaxime and
methicillin, effected the most rapid decline in viable counts during the first 6 h of
treatment, while the remaining antibiotics also showed excellent activity against
L. pneumophila throughout the course of th ese experiments. Of those tested,
cefotaxime most effectively reduced organism viability and induced the most
dramatic morphological c h a n g e s at the time intervals investigated.
Morphological studies.

U n treated . Negative stain, scanning and

thin-section electron microscopy studies of normal control organism s revealed
the typical ap p earan ce of legionellae and confirmed the findings of others.
Most cells w ere 2-10 pm long and 0.25-0.5 pm wide. The bacterial surface of
normal cells w as rugose and ruffled in appearance. O rganism s showed a cell
wall structure consistent with that of gram-negative bacteria. A lipid bilayer, or
cytoplasmic mem brane, enclosed the cytoplasm which consisted of ribosomes,
a small num ber of intracellular vacuoles and a fine skein of nuclear elements.
The latter were distributed evenly throughout the bacterial cytoplasm. The outer
m em brane enveloped the periplasm which showed little structural evidence of a
peptidoglycan layer (plate 4.1).
Cell wall inhibitors. Cefotaxime treatm ent. Cefotaxime at 20 times
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the MIC c a u s e d extreme d am ag e to microorganisms. Incubation with this
antibiotic for 6 h resulted in the formation of lesions and lytic points in the cell
walls of a greater number of bacteria than any of the antibiotics studied at this
time period. Extrusion of the bacterial cytoplasmic contents through such lytic
points w as the most common feature noted. Bulbous vesicles were observed
on the surface of cells and many organisms p o s s e s s e d diffuse electron-lucent
cytoplasmic contents. Extension of treatment with cefotaxime to 24 h resulted in
an increase in d am ag e to th ese cells in terms of the degree of m em branous
lesions and vesicles induced in the cell surfaces a s well a s the number of
organisms affected. In addition, many bacteria lacked either cytoplasmic
contents or prokaryotic structure. The formation of spheroplasts w as not
observed (plates 4.2 and 4.3).
Methicillin treatm ent. Organisms grown in the presence of 20 times the
MIC of methicillin showed extensive morphological changes. Affected cells
exhibited cell wall and m em brane abnormalities and developed several lytic
points through which the cytoplasmic contents extruded into the surrounding
menstruum. Although many organisms app eared normal, spheroplast
formation w as evident at this stage. Incubation with methicillin for 24 h induced
a greater d e g re e of cell wall and m em brane d am ag e than the lesser incubation
period.

The outer m em brane of the majority of organisms w as found to have

sep arated from the remaining cell wall and the development of small vesicles
on the cell surfaces w as evident.

As a con seq u en ce of lysis of the inner and

outer m em branes, a loss of cytoplasmic material occurred (plates 4.4-4.S).

83

Protein synthesis inhibitor. Rifamoicin tre atm e n t. Exposure of L*
pneumophila to 20 times the MIC of rifampicin induced marked d a m a g e to
bacteria. Incubation for 6 h in the presence of this antimicrobial induced
m em brane d am ag e to the organism but this appeared less pronounced than for
the other antibiotics examined. Separation of outer m em branes from the
remaining cell wall and breakage points in the inner m em b ran es were evident
in affected microorganisms. In addition, the ribosomes of th e se cells were
enlarged, much increased in electron density and associated with a r e a s of
cytoplasmic clearing. Extended treatment with rifampicin elicited a more
pronounced effect in which lytic points in the m embrane of cells and loss of
intracellular contents led to eventual collapse (plates 4.9-4.12).
DNA inhibitor. Ciprofloxacin treatm ent. Organism s treated for 6 h with
20 times the MIC of ciprofloxacin exhibited marked morphological ch an ges.
The majority of cells were abnormally elongated forming filaments each of
which p o s s e s s e d centrally located "pinched zones" suggestive of arrested
division. The inner m em branes of many legioneilae were intermittently lysed
and separated from th e remaining cell wall material. In addition, the
intracellular contents of cells were more densely packed d u e to an apparent
overall increase in the size of individual ribosomes. Further exposure to this
antibiotic induced d a m a g e to 98% of the Legionella organism s present.
Twisted, convoluted bacteria were found with d ep ressed, partially collapsed
a re a s on their cell surface. In addition, som e organisms at this time had lost
their intracellular contents through breakage points in the cell wall while others
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maintained the densely packed cytoplasmic ap p earan ce found in 6 h antibiotic
treated organism s (plates 4.13-4.19).
Figure 4.7 shows the relative proportion of lysed and partially d am ag ed
cells com pared with th o se of normal morphology following antibiotic treatment
for both 6 a n d 24 h and Table 4.2 sum m arizes the morphological findings.
4.5

Discussion
Erythromycin is the preferred drug for the treatment of Legionnaires’

disease. However, b e c a u s e patients with severe illness often respond poorly to
antimicrobial therapy, new antibiotics are being studied for u se a s alternate
therapeutic regimens. In vitro screening of these potential ag en ts to determine
the activity a n d mode of action of th ese antibiotics must be performed in order to
evaluate s u b seq u en t in vivo and clinical trials. In the present study, the in vitro
effect of clinically relevant antibiotics, including the new quinolone,
ciprofloxacin, on the growth and morphology of L. pneumophila w as examined.
Electron microscopy studies have been important for the delineation and
understanding of antimicrobial activity against many pathogenic
microorganisms (61, 77, 141). Elliott and Rodgers (35,107, 109) evaluated the
morphological and growth response of L. pneumophila following exposure to
ampicillin an d erythromycin for 6 and 24 hours using electron microscopy, MIC
determinations and microbial viable count data. In that investigation, ampicillin
exhibited g re a te r bactericidal activity an d induced more ultrastructural ch a n g e s
than erythromycin in vitro.

Ampicillin treatment c a u s e d the ap pearan ce of

vacuole-like lesions in the cell walls of organisms which led to extensive
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bacterial lysis and collapse of legionellae while exposure of L. pneum ophila to
erythromycin effected occasional breakage points in the cell wall along with
cytoplasmic clearing, formation of m em branous vesicles and som e cell lysis.
In this study, all antibiotics tested w ere effective against L. pneumophila
as a s s a y e d by MIC data, the reduction in bacterial viable counts and
morphological resp o n se induced.

Methicillin showed extrem e bactericidal

activity against multiplying organisms in broth culture. This was confirmed by
the morphological studies in which many lysed and empty cells were evident
after 6 and 24 h exposure periods. Formation of spheroplasts following
treatment with 1280 pg/ml of this antibiotic w as dem onstrated and confirmed
previous observations by Elliott and Rodgers of this phenom enon with another
cell wall inhibitory antibiotic, ampicillin (35). T hese data su g g ested that the
formation of minicell-like organisms and spheroplasts upon exposure to cell
wall inhibitory antibiotics such a s methicillin and ampicillin may constitute a
m echanism by which osmotically protected legionellae survive within host cells
and continue infection following reversion to vegetative forms upon
discontinuation of therapy. Such findings may offer an explanation for the
reported apparent "reactivation" infections due to L. pneumophila and may
reflect ineffective killing of the organism in vivo in human lung.
C h an et al. (19) reported similar spheroplast formation for methicillin
used at 100 pg/ml, but could not dem onstrate this phenom enon with increased
d oses of up to 1000 pg/ml of methicillin. It is possible that the addition of
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m agnesium salts to the fixatives and buffers u se d in the present study could
have stabilized fragile bacterial m em branes and may account for the
differences in spheroplast detection.
Cefotaxime show ed the greatest bactericidal activity an d this resulted in
the most rapid decline in numbers of viable organisms. Indeed, this third
generation cephalosporin induced the greatest morphological changes in
microbial cytology at either of the exposure times. These results conflicted with
th ose of Chan et al. (19) who reported no morphological c h a n g e s in resp on se
to treatment of L. pneumophila with different d o s e s of this antibiotic. It w as
interesting to note that this drug failed to induce spheroplast formation by L.
pneum ophila although a similar finding was reported following treatment of
other gram negative bacteria with increased levels of cephalothin (8 8 ).
Although most Legionella species produce (3-lactamases, the p-lactam
antibiotics are most effective against actively dividing L. pneumophila cells in
vitro. In this study, antibiotics were added in the mid-exponential p hase of
growth, which for L. pneumophila using the broth selected an d an inoculum of
10 5 cfu/ml w as achieved 24 h into the growth cycle, to allow th e s e agents to
function at their full capacity. Failure of Chan et al. (19) to detect similar
morphological c h a n g e s d u e to this antibiotic may have reflected the nonreplicative status of the organisms subjected to antimicrobial treatment.
Ciprofloxacin and rifampicin showed effective bactericidal activity in
viable count estimations at all the times studied. Despite showing the g reatest
activity in MIC assay s, th e se antibiotics induced only moderate structural
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d am ag e after short term exposure. However, such ch an g es increased with
treatment time. That bacterial viability was lost prior to the induction of
extensive ultrastructural d am ag e probably reflected the m ode of action of th e se
antimicrobial agents against L. pneumophila cells in the exponential p h ase of
growth.
Results from this and other studies (35, 107, 109) dem onstrated that the
cell wall inhibitory antibiotics were the most effective in term s of their ability to
reduce L. pneumophila viability and induce morphological d am ag e in vitro.
Although all the antibiotics investigated in this study showed in vitro
antimicrobial activity against L. pneumophila, it h as been reported that the
aminoglycosides, cephalosporins, and penicillins including ampicillin and
methicillin were clinically ineffective in the treatment of legionellosis (82).
B ecause of its intracellular nature, L. pneumophila can avoid the effects of
antimicrobial ag en ts that lack the ability to penetrate host cell membranes.
Indeed, it has been reported that ciprofloxacin, erythromycin and rifampicin (65,
130) inhibit intracellular L. pneumophila growth while the (5-lactam antibiotics
such a s ampicillin, cefoxitin and cefotaxime do not (142). This most likely
explains the efficacy of erythromycin and rifampicin in the clinical treatment of
human legionellosis and em phasizes the need for further in vivo testing of
ciprofloxacin a s a potential alternative to current clinical therapeutic regimens.
That bacteria with apparently normal morphology w ere found following
extended incubation with all antibiotics examined in this study and in similar
experiments performed by Elliott and Rodgers (35) with ampicillin and
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erythromycin may offer further explanation for failure of current antimicrobial
therapeutic protocols for the treatment of clinical Legionnaires' disease.

In

addition, th ese results considered in combination with reports of increasing
incidence of bacterial resistance to standard antibiotic regimens indicated a
continued need for thorough in vitro investigation of the respo nse of pathogenic
ag e n ts to antimicrobial chemotherapy.
T hese d a ta illustrate the in vitro activity and mode of action of clinically
relevant antibiotics for the treatment of Legionnaires' d isease. This information
is n ecessary to the understanding and evaluation of su b seq u en t in vivo trials
investigating the activity of th e s e agents for the treatment of experimentally
infected animal system s and for potential therapy of clinical disease.
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Table 4.1 Susceptibility of L. pneumophila to se le c te d antibiotics
Antibiotic

MIC (pg/m l)i

Cell wall inhibitors
cefotaxime
methicillin
(ampicillin

8.0
64
0.4)2

Protein synthesis
inhibitor
rifampicin
(erythromycin

0.03
0.5)2

DNA inhibitor
ciprofloxacin

0.08

1For viability and ultrastructural studies antibiotics were a d d e d to broth cultures
at a final concentration of 20 times the MIC, respectively.
2Data for ampicillin and erythromycin reproduced with permission (Elliott and
Rodgers, J. Med. Microbiol., reference 35) and are included here to complete
the comparative profile. Data were derived in a similar m anner a s for the other
antibiotics.
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Table 4.2
hours.

Morphological response of L. pneumophila following exposure to antibiotics for 6 and 24

Feature

Antibiotic
Cef
6 h 24h

formation of lesions in cell wall
cytoplasmic clearing
membrane vesicle formation
spheroplast formation
m embrane abnormalities
enlargement of ribosomes
plasmolysed cells
convoluted organisms

Meth
Amp 1
6 h 24h 6 h 24h

+

+

+

+

+

+

+

+

+

+

+

Erv1
6 h 24h

Rif
6 h 24h

Cipro
6 h 24h

+

+

+

+

+ /-

-

-/+

+

+

-

-

-

-

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

-

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-/+ +

+

+

+

+

+

+

o>
1From reference 35, Elliott and Rodgers, J. Med. Microbiol., with permission. Data included to
complete comparative prolile.
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Figure 4.1 Growth of L. oneumoohila in BYEa broth ( ■

■ ). The effect on

bacterial viability of cefotaxime ( ♦
♦ ) added during the mid-exponential
p h a s e of growth (arrow) is shown. This antibiotic w as very effective at reducing
bacterial viability.
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Figure 4.2 Growth of L. pneumoohila in BYEa broth ( ■

■ ). The effect on

bacterial viability of methicillin ( ♦
♦ ) ad ded during the mid-exponential
p h ase of growth (arrow) is shown. This antibiotic was very effective at reducing
bacterial viability.
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Figure 4.3 Growth of L. pneumophila in enriched blood broth. The effect on
bacterial viability of ampicillin added during mid-exponential phase of growth
(arrow) is shown. This antibiotic effected a rapid decline in viable counts but
w as not bactericidal for the entire bacterial population. D ata reproduced with
kind permission (Elliott and Rodgers, J. Med. Microbiol.. reference 35) and
included here to complete comparative analysis. Growth of L pneumophila in
this broth had a m ean generation time of 2.0 h.
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Figure 4.4 Growth of L. pneumophila in enriched blood broth. The effect on
bacterial viability of erythromycin added during mid-exponential p h ase of
growth (arrow) is shown. This antibiotic w as th e least effective in term s of
bactericidal activity. Data reproduced with kind permission (Elliott and Rodgers,
J. Med. Microbiol., reference 35) and included here to com plete comparative
analysis. Growth of L. pneumophila in enriched blood broth had a m ean
generation time of 2.0 h.
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Figure 4.5 Growth of L. pneumophila in BYEa broth ( ■

■ ). The effect on

bacterial viability of rifampicin (
^ ) add ed during the mid-exponential
phase of growth (arrow) is shown. This antibiotic showed marked antibacterial
activity.
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Figure 4.6 Growth of L. pneumophila in BYEa broth ( ■

■ ). The effect on

bacterial viability of ciprofloxacin { ^
♦ ) added during the mid-exponential
p hase of growth (arrow) is shown. This antibiotic show ed marked antibacterial
activity.
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Figure 4.7 Proportion of bacterial cells showing normal morphology ( Q ) and
those d am ag ed $ H ) after exposure for 6 or 24 h to the various antibiotics at 20
times their respective MIC values. Percentages were calculated from counts of
100 or more cells for each agent and for each treatment time. Data in boxed
a re a is reproduced with permision (Elliott and Rodgers, J. Med. Microbiol.,
reference 35) and is included for the purposes of comparison.
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Plate 4.1 Untreated, control Legionella organisms showing normal
morphology. The bacterial surface is ruffled and the cell wall structure is
co m p osed of a double track m em brane with little visual evidence of a
peptidoglycan.
a) negative stain (X 18,000), b) scanning (X 30,000), c) thin-section (X 40,000).
Bars=0.5 pm.

99

Plate 4.2 L. pneumophila organisms exposed to cefotaxime for 6 h.
a) note bulbous vesicles on the surface of the organism, scanning (X 20,000),
b) organism showing loss of intact mem brane structure surrounding diffuse,
electron-lucent cytoplasmic contents, thin-section (X 40,000), c) bacterium with
ad v an ced m em brane dam age and associated loss of cytoplasm, thin-section
(X 60,000). Bars=0.25 \im.
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Plate 4.3. Legionellae exposed to cefotaxime for 24 h.
a) formation of lytic points (arrow) in the bacterial cell wall, negative stain
(X16,000), b) collapsed organism with abnormal surface structure, scanning
(X 30,000), c) plasmolyzed organism with loss of prokaryotic structure, (thinsection (X 80,000). a, b Bars=0.5 pm, c Bar=0.25 pm.
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a

Plate 4.4 L. pneumophila exposed to methicillin for 6 h.
a) L. pneumophila organism with breakage point in cell wall (arrow), negativestain (X 16,000), b) advanced sta g e of lysis-cytoplasmic contents extruding
through lytic point in the cell wail of an organism, negative-stain (X 18,000).
Bars=0.5 pm.
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Plate 4.5 Legionellae exposed to methicillin for 6 h.
a) d a m a g e d bacterial cells surrounding an apparently normal cell, thin-section
(X 30,000), b) spheroplast formation is evident alongwith deformed and normal
cells, thin-section (X 40,000). Bars=0.25 pm.
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Plate 4.6 L. pneumophila exposed to methicillin for 6 h.
a) severely dam ag ed cells with abnormal m embrane distortion (arrow), thinsection (X 40,000), b) plasmolyzed organism with pinching and ballooning of
m em branes, thin-section (X 80,000). Bars=0.25 pm.
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Plate 4.7 Legionella organisms exposed to methicillin for 24 h.
a) note loss of cytoplasmic contents through advanced lytic point in bacterial
cell wall (arrow), negative-stain (X 12,000), b) induction of num erous blebs on
the microbial surface, scanning (X 20,000). Bars=0.5 pm.
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Plate 4.8 L. pneumophila exposed to methicillin for 24 h.
a) com plete loss of bacterial cytoplasmic contents with extrem e dam age to the
microbial cell walls, thin-section (X 40,000), b) organism devoid of cytoplasm
with associated inner and outer membrane separation, thin-section (X 40,000).
Bars=0.5 pm.
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Plate 4.9. Organisms exposed to rifampicin for 6 h.
a) note numerous breakage points in the cell wall and loss of cytoplasm from
cell (arrows), negative-stain (X 16,000), b) extrusion of cytoplasm w as evident
(short arrow) a s well a s regions of bacterial collapse (long arrow), scanning (X
25,000). Bars=0.5 pm.

a

c

Plate 4.10 L. pneumophila exposed to rifampicin for 24 h.
a) darkly staining surface lesions and num erous small vesicles present,
negative-stain (X 16,000), b) distorted, partially collapsed organisms, scanning
(X 15,000), c) disruption of ou ter m em brane and increased size an d density of
ribosomal content of cells, thin-section (X 70,000).
a, b Bars=0.5 pm, c Bar=0.25 pm.
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Plate 4.11 Organisms exposed to rifampicin for 24 h. Note localized zo n es of
increased density and size of ribosomes within cytoplasm a s well as distorted
m em brane structure of cells (arrow), thin-section (X 34,000). Bar=0.25 pm.

Plate 4.12 Organisms ex po sed to rifampicin for 24 h. Increased density of
cytoplasmic contents is evident in addition to separation of cell walls from
remaining cell contents, thin-section (X 34,000).
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Plate 4.13 L. pneumophila exposed to ciprofloxacin for 6 h.
a) darkly staining lesions in cell wall of a partially collapsed organism, negativestain, (X 24,000), b) convoluted organism with centrally located pinched zone,
scanning (X 20,000). Bars=0.5 pm.
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Plate 4.14 L. pneumophila exposed to ciprofloxacin for 6 h. Note severely
deformed cell (arrow) with a re a s of cytoplasmic clearing and abnormal
m em brane structure, thin-section (X 34,000). Bar=0.25 urn.
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Plate 4.15 L. pneumophila exp osed to ciprofloxacin for 6 h. Abnormal
distribution of ribosomes alongwith a re a s of localized clearing within the
bacterial cytoplasm of cells, thin-section (X 40,000). Bar=0.25 pm.

Plate 4.16 Legionellae exp o sed to ciprofloxacin for 6 h. Note vesiculation of
bacterial cytoplasm (arrow) a n d increased size and density of ribosomes, thinsection (X 60,000). Bar=0.25 pm.

Plate 4.17 L. pneumophila exposed to ciprofloxacin for 6 h. Single cell showing
very d e n s e ribosomal contents within bacterial cytoplasm, thin-section
(X 60,000). Bar=0.25 ^m.
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Plate 4.18 L. pneumophila exposed to ciprofloxacin for 24 h.
a) twisted, convoluted organism with multiple pinched zones, negative-stain (X
12,000), b) filamentous, twisted organisms are evident, scanning (X 10,000), c)
partially collapsed organism with centrally located pinched zone, scanning
(X 34,000). a, b Bars=0.5 p.m, c Bars=0.25 urn.
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Plate 4.19 L pneumophila exposed to ciprofloxacin for 24 h. O rganism s
showing various types of morphological response to treatment. S o m e cells
have lost their cytoplasmic contents (short arrow) while others exhibit increased
ribosomal density (long arrow). Note twisted, abnormally shaped cell
morphologies, thin-section (X 24,000). Bar=0.5 pm.
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Se ction V

Pathogenesis, Pathology and Chemotherapy of Experimental
Legionella pneumophila Infection in the Chick Embryo

5.1 Abstract
The pathogenicity of Legionella pneum ophila, serogroup 1 , strain
Nottingham N7, was a s s e s s e d in terms of LD50 d ata and the ability of the
organism to induce histopathoiogical and ultrastructural lesions in the fertile
hen's egg. Histological examination of embryo organs after inoculation with 1 ,
10 , 100 an d 1000 times the yolk s a c LD50 revealed a dissem inated infection.

Systemic s p read of the organism resulted in the a p p e a ra n c e of pathological
lesions an d the generation of edem a fluid. These were particularly se v e re in
the liver, heart, spleen and kidney. Electron microscopy of the pathology
induced in organs of chick embryos previously infected with 100 times the
YSLD 50 of L. pneumophila confirmed th ese observations. Subtle pathological
ch an g es w ere noted three days post-inoculation while more extensive cellular
and sub-cellular necrotic chang es occurred at four d ays post-inoculation. The
infection elicited an inflammatory cell response that consisted of
polymorphonuclear leucocytes and lymphocytes. S elected antimicrobial
agents were investigated in therapeutic studies for their capacity to ameliorate
or control d ise a se p ro c e ss e s in this test system. Of th o se examined,
ciprofloxacin was most effective at reducing or reversing the incidence of
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lesions in th e se tissues and for prolonging embryo viability. Rifampicin, and to
a lesser d eg ree, erythromycin and doxycycline, also showed antimicrobial
activity in th e se in vivo trials. These results illustrated the efficacy of the fertile
h e n ’s egg a s a useful alternative in vivo a s sa y system for the evaluation of
clinically putative antimicrobial agents in the treatment of Legionnaires'
d isease. In addition, this study dem onstrated the superior antimicrobial activity
of ciprofloxacin in the treatment of experimentally induced Legionella infections.
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5.2

Introduction
L- pneumophila is the etiological agent of legionellosis which in the

severe pneumonic form presents a s Legionnaires’ d isea se (85). Despite the
accumulation of considerable d a ta describing the invasive nature of the
microorganism, the pathogenic m echanism s by which this gram-negative rod
cau ses infection are not well understood. In human d ise a se and experimental
animal infections, the legionellae are facultative intracellular pathogens which
survive a n d replicate within alveolar macrophages.
Although primarily recognized as a pneumonic illness, Legionnaires'
disea se h a s been shown to produce a widespread bacterem ia alongwith the
a p p e a ra n c e of soluble L. pneumophila antigen in clinical sam ples of serum and
urine (12) in association with extrapulmonary pathology (13, 115). Multi-organ
inflammatory lesions due to Legionella bacteremia are not common but have
been described (24). Because Legionnaires' d isea se first presents a s a classic
pneumonic infection, the extra-thoracic asp ects of the d ise a se have been
overlooked, but it is evident that the serious pathological seq uelae that result
from L. pneumophila infection may play a larger role in the overall d ise a se
process th an was previously suspected.
Numerous antibiotics with different m odes of action have shown activity
against L. pneumophila in vitro (30, 35, 60, 109, 112, 123). However, many of
these antibiotics with effective minimum inhibitory concentrations (MIC) are
reported a s ineffective in the treatment of Legionnaires' d ise a se (82) while
others su c h as erythromycin, rifampicin, and to a lesser extent, the tetracyclines
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have been efficacious in therapy (2). Erythromycin is considered the drug of
choice for Legionnaires' disea se but variable clinical resp o n ses in patients to
this antibiotic and problems associated with low d o s e or intravenous
erythromycin therapy have been reported (62). Consequently, other therapeutic
options are currently sought.
The quinolones are antimicrobial agents that effectively inhibit bacterial
DNA gyrase activity. O ne member of this group, ciprofloxacin, is a promising
new lipid soluble antibiotic with broad spectrum activity and the ability to
penetrate eukaryotic cells. This antibiotic has few side-effects, offers oral
bioavailability, achieves high tissue concentrations an d has been used
successfully in the treatment of various urinary and respiratory tract infections.
Ciprofloxacin has been shown to be very active against L. pneumophila in vitro
(60, 65) and in experimental Legionella infections of guinea pigs (44, 45, 135).
B ec au se treatment of human legionellosis often com m ences well after
o nset of d isea se, controlled clinical studies exploring the use of alternative
chem otherapeutic agents are difficult to perform and force researchers to
d ep en d on animal studies for data accumulation. Although in vivo testing of
antibiotic efficacy in guinea pigs has thus far correlated well with clinical data,
investigators using this animal system for th ese studies require specialized
equipment, animal laboratory facilities, specialized expertise, and, according to
current regulations, qualified staff, animal care and u s e permission, and in
s o m e countries animal licenses. In addition, the cost and availability of these
animals limits the use of significant num bers in experiments and m akes
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interpretation of data difficult. It is clear that the ability to test alternative
therapeutic regimens for the treatment of Legionnaires’ d isea se has becom e
increasingly important and n ecessitates the development of a simplified and
reproducible in vivo antimicrobial assay system.
Lewis et al. (83) introduced the u se of embryonate egg s to examine in
vivo prophylactic and post-infection antibiotic therapy of experimental
legionellosis following th e initial outbreak of Legionnaires' d isea se in
Philadelphia in 1976. This study evaluated antimicrobial therapy b a s e d on the
ability of antibiotics to reduce mortality rates of infected em bryos and yielded
results in keeping with clinical findings. In the present study, the chick embryo
w as used to delineate the baseline histological and ultrastructural pathology
associated with the progression of experimental infection in this animal with L.
pneum ophila in order to determ ine the therapeutic value of antimicrobial agents
introduced into this animal following experimental infection. Results from these
investigations were used to evaluate the chick embryo a s an alternative in vivo
a s s a y system for the testing of new and/or putative antimicrobial ag e n ts in the
treatment of hum an legionellosis. In addition, the quinolone antibiotic
ciprofloxacin w as exam ined for its chemotherapeutic activity and com pared with
clinically relevant antibiotics for its effectiveness at regulating infection in the
chick embryo animal system.

Elucidation of the m echanism s of pathogenesis

an d growth of L. pneumophila in this in vivo host system and the role of
antimicrobial therapy in the d isea se process may have an impact on current
p rocedures for the m aintenance and care of patients with legionellosis.
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5.3

Materials and Methods.
R eagent formulations and preparations along with detailed procedures

are given in Appendices 1 , 2 , 3 , and 4.
Preparation of bacterial inocula.

L. pneum op hila, serogroup 1 ,

strain Nottingham N7, was isolated from the sputum of a fatal c a s e of
Legionnaires' d ise a se , subsequently p a ssa g e d twice on bacteriological media
and maintained frozen at -70° C in 10% serum with added 1% sorbitol. Thawed
aliquots were grown at 37°C on buffered charcoal yeast extract agar enriched
with L-cysteine, ferric pyrophosphate and a-ketoglutarate (BCVEa) (29) and
incubated aerobically for 48 hours. Organisms were harvested in 5 ml
p hosphate buffered saline pH 6.9 (PBS) to give a density equivalent to 108
colony forming units (cfu)/mi a s determined by a Klett-Summerson photoelectric
colorimeter. Organism m ass, expressed in terms of viability, w a s determined in
duplicate a s cfu on BCYEa to confirm opacity data.
Egg type, incubation, inoculation route and determination of
LD 5 0 s. Antibiotic free, fertile White Leghorn hens' eggs (UNH Poultry Farm)
were incubated at 36°C in a humid atmosphere. Organisms w ere introduced
into e g g s by four inoculation routes: allantoic and amniotic s a c s (at 10 days of
embryo incubation), chorioallantoic membrane (CAM) and yolk s a c (at 7 days of
embryo incubation) (Figures 5.1 an d 5.2). Sixty embryonate e g g s were used for
each inoculation route. Serial 10-fold dilutions of L. pneumophila in PBS were
m ade and those ranging from 1 01 to 106 cfu/ml were inoculated at a rate of 10
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eg g s per dilution. Inoculated eg g s were incubated and candled twice daily to
check for embryo viability. Mortality and protection experiments were performed
three times and the LD50 for each inoculation route w as determined from the
av erag ed mortality d ata by the method of Reed and Muench (101).
Recovery of organisms and histopathoiogy studies.

Organism

m a s s w as calculated a s described and the inocula adjusted to give inoculation
d o s e s equivalent to 1, 10, 100 and 1000 times the yolk s a c LD50 {YSLD50).
Each multiple d o se LD50 of L. pneumophila was inoculated into the yolk s acs of
fertile eg g s and th e se were harvested at 24 hour intervals from one to eight
day s post-inoculation. Organ sam ples including liver, heart, spleen an d kidney
w ere removed aseptically from embryos, rinsed thoroughly in PBS and
weighed. O rgans were homogenized in a Sorval Omni Mixer, serially diluted
and aliquots inoculated onto BCYEa for viable count assay . Colony counts
were exp ressed a s cfu/gram of tissue and were calculated for each organ at
each time interval in triplicate. Similarly inoculated and control eg g s were
harvested and whole embryos a s well a s sam ples of liver, heart, spleen and
kidney were fixed in 10 % buffered formalin and em bedd ed in paraffin wax in a
Lab Tek Tissue Processor. Four micron thick sections w ere cut, deparaffinized
and routinely stained with hematoxylin and eosin for histopathological
examination.
Immunofluorescence.

Deparaffinized tissue sections and tissu e

hom ogenates were incubated with a 1 in 50 dilution of rabbit anti-L.
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pneumophila serum , followed by incubation with a 1 in 200 dilution of FITCconjugated goat anti-rabbit serum (Cappel Laboratories, Malvern, Pa.). All
labelling steps w ere followed by 3-fold washings in PBS to remove unbound
globulins.
E lectro n m ic r o s c o p y s tu d ie s .

E ggs were inoculated with 100 times

the YSLD50 by the yolk sac route, and the embryo organs, liver, heart, spleen
and kidney, harvested at 24 h intervals and prepared for electron microscopic
examination. T issue sam ples were rinsed in 0.1 M cacodylate buffer, pH 7.2
(CB) fixed in 3% (v/v) glutaraldehyde in CB for 24 hours, post-fixed in 1% (w/v)
osmium tetroxide (OSO 4 ) in CB for two hours and dehydrated in a graded
ethanol series. Sam ples were em bedded in an epon-araldite resin mixture and
polymerized for 24 hours at 60° C (105, 108). Thin sections, cut on an LKB
Ultratome III with a diamond knife, were stained with 5% (w/v) uranyl acetate
and 0.4% (w/v) lead citrate an d examined by transmission electron microscopy
in a Hitachi H600 electron microscope u se d at 80kV.
Antibiotic therapy studies. MIC values were calculated for
ciprofloxacin (Miles Pharmaceuticals, West Haven, Ct.), erythromycin,
doxycycline and rifampicin (Sigma Chemicals, St. Louis, Mo.) by a standard
ag a r dilution technique (133) using BCYEa. For these experiments, eg g s were
infected by the yolk s a c route with 100 times the YSLD50 of L. pneumoohila.
For histopathological studies, one or ten times th e MIC of e a c h of the four
antimicrobial ag e n ts were administered intra-allantoically at one day post
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inoculation. Mortality d ata were calculated with time for each antibiotic and
bacterial viable counts determined from embryo organ hom ogenates. Similar
sam ples were harvested and prepared for histological examination to a s s e s s
the ability of each antibiotic to inhibit either an inflammatory cell response or the
developm ent of pathological lesions in embryo organs.
Antibiotic therapy of chick embryos was com m enced at three days post
infection for electron microscopic investigations. This schedule was selected
b e c a u s e electron microscopic studies of untreated control sam ples showed that
this time interval allowed for the earliest expression of ultrastructural
pathological lesions to develop after the introduction of L. pneumophila into the
chick embryo. In such treatments, 10 times the MIC levels of each of the four
antibiotics w ere administered intra-allantoically and organ sam p les of liver and
kidney from viable embryos were harvested for electron microscopy at four and
eight days post-inoculation (one and five days post-therapy, respectively).
5.4

Results
Pathogenesis. The LD50 values for L. pneumophila introduced into

the embryonate egg were determined and are illustrated in Table 5.1. The
inocula required to induce embryo death ranged from 1.4 X 10 2 cfu/ml for the
amniotic sa c to 5.5 X 10* cfu/ml for the allantoic sac. The LD50 studies
dem onstrated that those inoculation routes which a c c e s s e d the immediate
environment or the nutritional source of the embryo required lower organism
num bers to induce fatal infections com pared with more peripheral routes.
Inoculation of multiple d o ses of the YSLD50 into fertile h en s’ eggs
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resulted in dissemination and growth of Legionella organisms in the liver, heart,
spleen and kidney. A tissue resp o nse and d o se effect w as observed in that
viable counts on harvested organs of embryos infected with 1 or 10 times the
YSLD50 revealed that exponential bacterial growth began at four d ay s post
inoculation in the liver and heart but after five d ay s in the spleen and kidney
(Figures 5.3 and 5.4). In addition, bacterial a s s a y s of organs from embryos
inoculated with 100 and 1000 tim es the YSLD50 showed that organism growth
began at four days post-inoculation in all exam ined organs (Figures 5.5 and
5.6). Microbial a s s a y of tissues at eight days post-inoculation with 1000
YSLD50 yielded counts ranging from 3.3 X 10 4 to 9.9 X 105 cfu/gram in the
kidney and liver, respectively (Figure 5.6). Organism concentration in organs
w as highest in the liver and lowest in the kidney irrespective of the multiple
d o se u s e d a s inoculum.
Histopathology. Gross examination of the organs of embryos infected
by various routes of inoculation with multiple d o s e s of the YSLD50 showed no
ostensible lesions. Inoculated CAMs failed to dem onstrate visible pocks or
pathological chang es. Following yolk sac inoculation, histopathological
examination on organs of embryos infected with 1 , 10 , 100 and 1000 times the
YSLD50 revealed pathological ch an g es in the liver, heart, spleen and kidney
and w ere most evident in regions rich in blood vessels (plates 5.1-5.5). With
inocula of 1 , 10, or 100 times the YSLD50 an inflammatory cell response
ap peared simultaneously at five days post-inoculation in all organs examined
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but at four days following administration of 1000 times the YSLD50. At this
stage, congestion of the blood vessels within tissues were most evident (plates
5.1 -5.2). Heart tissue showed marked vascular congestion with evidence of an
ed em ato us resp o n se (plate 5.2). In the kidney, pathological ch a n g e s in the
glomeruli, with an associated cell exudate, were evident as com pared with the
relatively u nd am ag ed convoluted tubules (plate 5.4).
Histopathological examination of sections at higher magnification
show ed degenerative in each organ typified by breakdown of cell and nuclear
m em brane structure, loss of cell components, and margination of nuclear
chromatin. Darkly staining PMNLs and leucocytes were also common (plate
5.5). T hese results are summarized in Table 5.2.
Immunofluorescence. The p resence of L. pneum ophila organisms in
situ in tissue sections and hom ogenates w as confirmed by specific
immunofluorescence. Labelled organisms were visualized along with tissue
d a m a g e in liver, heart, spleen and kidney sections of embryos previously
inoculated with multiple d o s e s of the YSLD50.
Ultrastructural pathology. Electron microscopic examination of the
liver, heart, spleen, and kidney of infected chick embryos revealed extensive
pathological d a m a g e at the cellular and sub-cellular levels. T h e se
observations are summarized in Table 5.3. The ultrastructural tissue dam age
induced by the organism w as similar in all organs examined and the earliest,
most tenuous pathological c h a n g e s were observed at three d a y s post
inoculation. Mitochondrial d a m a g e was evident at this time (plate 5.6 and 5.7).
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Major ultrastructural ch a n g e s occurred at four days post-inoculation and
consisted of extensive degenerative ch a n g e s which included fatty degeneration
and cytoplasmic clearing. T h ese ch a n g e s were characterized by ballooning
and breakdown of the cellular and nuclear mem branes, nuclear clearing,
margination of chromatin material, and cytoplasmic vesiculation (plate 5.8). A
hemolytic p rocess (plate 5.9) w as evident in these tissues. During latter stages
of the infection, many lysed, swollen or apparently empty mitochondria were
distributed throughout the cytoplasm of affected cells. At this stage, the nuclei of
many cells exhibited pyknosis or karyolysis (plate 5.10-5.12). In addition,
lysosomal bodies were present within cells presumably involved with autolysis
of th ese tissues. Occasionally, small num bers of legionellae were observed
within cells of embryo organs (plate 5.13).
Antibiotic therapy studies. The MICs of ciprofloxacin, doxycycline,
erythromycin and rifampicin for L. pneumophila are shown in Table 5.4. Of the
four antibiotics, ciprofloxacin at 10 times the MIC proved most effective in
delaying tissue d a m a g e and preventing an inflammatory cell respo n se prior to
eight days post-inoculation a s a s s e s s e d by histopathological examination.
Erythromycin, doxycycline or rifampicin effected a delay in th e development of
th e se lesions, but their effect w as much less pronounced. T h e se results are
shown in Table 5.4. Only embryos protected with ciprofloxacin survived to term.
In addition, the efficacy of th e se antibiotics w as evaluated in bacterial viable
count as sa y s performed on organs of embryos previously infected eight d a y s
previously with 100 times the YSLD50 of L. pneumophila. Results are shown in
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Figure 5.7. At 10 times their MIC, ciprofloxacin was more efficient at reducing
organism num bers in th ese tissues than either erythromycin or rifampicin.
Figure 5.8 sho w s the results of embryo viability after inoculation with 100 times
the YSLD50 of L pneumophila with administration 24 hours later of 10 times the
MIC levels of ciprofloxacin, erythromycin or rifampicin. Ciprofloxacin g av e the
highest p ercentag e of embryo survival throughout the trials. Eight day s post
inoculation the survival rate for embryos protected with ciprofloxacin w a s 83%
com pared with rifampicin at 33% or erythromycin at 10%. By 14 days p ost
inoculation all rifampicin or erythromycin treated embryos had succum bed to
infection.
Ultrastructural observations of infected embryo organs treated three days
subsequently with 10 times the MIC of th e se antibiotics showed similar changes
and are sum m arized in Table 5.5. Only viable embryos w ere processed for
electron microscopic examination. Ultrastructural tissue d am ag e in
erythromycin (plate 5.14) and doxycycline (plate 5.15) treated embryos w as less
sev ere than unprotected tissu es at four days post-inoculation. Indeed, the
cellular ch a n g e s at this stage in the presence of erythromycin were similar in
app earan ce to th ose at day three of infection in the a b s e n c e of antibiotic.
T issues from rifampicin treated embryos also showed le ss dam age than
controls and w ere comparable at four and eight days post-inoculation (plates
5.16 and 5.17). However, tissu es from ciprofloxacin treated embryos w ere
found to be consistently less d am aged at eight days than at four days p o st
infection (plates 5.18 and 5.19) indicating that the degenerative process
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associated with infection at the ultrastructural level had been reversed.
5.5

Discussion
In keeping with current p ressu res and legislation to reduce vertebrate

animal u se in research an d diagnosis, the self-contained em bryonate hen's egg
offers an alternative in vivo antibiotic assay system for L. pneumophila. Eggs
are relatively easy to handle, inexpensive, and can b e used in sufficiently large
numbers to test each antibiotic so a s to give significant a s s e s s m e n t levels
normally unattainable with other laboratory animals. In addition, no specialized
animal facilities, equipment, personnel or licenses a re required.
The LD5o studies revealed the high degree of pathogenicity of L
pneum ophila for this animal. These findings reflected the relative few num bers
of microorganisms required to achieve these mortality data and illustrated the
extreme infectious nature of the bacterium for the chick embryo a n d its tissues.
The rapid growth of L. pneumophila in the liver, heart, spleen a n d kidney
following inoculation with multiple d o s e s of the YSLD50 indicated that growth of
the organism in the chick embryo w as characterized by a bacterem ia with
satellite infections in th e se organs. Microbial a s s a y s also revealed that
irrespective of the inoculum dose, extensive organism growth occurred within
organs all organs examined, most notably in the liver but to a le s s e r degree in
the kidney. T h e se data supported similar observations by other workers that
organism s were found within the extrapulmonary o rg a n s of h u m an s and
animals previously infected with L. pneumophila.
Correlation exists between hum an legionellosis and experimental
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infections in various animal models. Pyrexia, antibody production, cellmediated immunity and bacteremia have been dem onstrated in various
laboratory animals. In addition, the production of inflammatory cells in response
to experimental and natural infections with the organism is often similar and
consists of a mixed infiltrate of PMNLs and m acrophages. Histopathological
examination of the liver, heart, spleen and kidney of the chick embryo following
inoculation with multiple d o s e s of L. oneumoohila revealed the simultaneous
ap p e a ra n c e of vascular cells in all organs and su gg ested a large scale
inflammatory cell response consisting primarily of PMNLs and lymphocytes.
Experimental infection of fertile hens' eg g s with L. pneumophila elicited
sev ere cellular and sub-cellular pathological ch a n g e s in all embryo organs
exam ined by electron microscopy. That ultrastructuraf tissue d am ag e w as
found to be similar and occurred synchronously three days post-inoculation in
th e se organs supported histopathological observations of a systemic-type
infection in this animal (128). The ultrastructural ap p earan ce of tissues of
infected embryo organs w as comparable to similar features exhibited in human
legionellosis (20, 21, 30, 105, 111).
Although L. pneumophila is sensitive to a variety of antimicrobial ag en ts
in vitro, the ability of this pathogen to replicate intracelluiarly limits the use of
many of th e s e ag en ts in vivo. Antibiotics which have been u se d successfully in
treatm ent include erythromycin, rifampicin and the tetracyclines. Animal
experim ents with guinea pigs previously exposed to aerosol suspensions of L.
pneum ophila and treated with clinically proven antibiotics readily dem onstrated
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the efficacy of rifampicin and to a lesser extent erythromycin. Effective
antimicrobial ag en ts were able to d e c re a se mortality and clear viable L.
pneumophila from the lungs but only rifampicin w as able to reverse
histopathological lesions (57). Similar results were obtained using L.
pneum ophila infected fertile hens' e g g s in which mortality d a ta was reduced by
treatm ent with rifampicin and erythromycin administered either prophylactically
or post-infection (83). To date, additional antimicrobial investigations have not
been performed to corroborate and extend th ese results.
Ciprofloxacin has shown excellent in vitro activity against L. pneumophila
in preliminary studies with agar and broth dilution tests a s well a s cell cultures
(65).

Effective ciprofloxacin treatment of experimental Legionella infection in

guinea pigs h as also been dem onstrated. In th e se studies, ciprofloxacin w as as
effective a s rifampicin and better than erythromycin in preventing death of
infected guinea pigs (44).
In the present study, the fertile hen's egg w as used a s an in vivo a s s a y
system for the critical evaluation of clinically useful antibiotics. Antimicrobial
ag en ts were administered one day post-inoculation and te ste d for their ability to
delay the development of histopathological lesions and the ap p earan ce of
infiltrative cells, reduce organism num bers in tissu es and d e c r e a s e embryo
mortality.

Ciprofloxacin, erythromycin, doxycycline and rifampicin were all

effective against L. pneumophila infection of the embryonated egg in all asp ects
of testing a s com pared with PBS controls. However, results from these
investigations dem onstrated the superior activity of ciprofloxacin in th ese in vivo
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trials.
The treatment of human legionellosis often com m en ces well after the
d isea se process is initiated. In this study, the progression of disease was
monitored at the ultrastructural level and antimicrobial therapy administered to
eggs to correspond with the ap p earan ce of the earliest cellular and sub-cellular
pathological ch an g es in tissues. It was evident that ciprofloxacin w as the most
effective antibiotic investigated b ased on its consistent ability to reverse
ultrastructural lesions induced in response to infection with L. pneumophila.
Although no animal system completely simulates the conditions of
human therapy, th ese results established the efficacy of the chick embryo to
evaluate clinically putative antibiotics for the treatment of human legionellosis
and to investigate the pathology associated with otherwise fatal experimental L.
pneumophila infections. The usefulness of ciprofloxacin in the treatment of
such infections in this animal w as also dem onstrated in all a sp e c ts of th ese
trials. Rifampicin, erythromycin and doxycycline also showed antimicrobial
activity in this a s s a y system, but to a lesser degree. Evidence from this and
other reports suggested that the u se of ciprofloxacin for the treatment of L
pneumophila experimental infections in animals requires further investigation.
In addition, studies are necessary to determine whether the u se of this drug may
be efficacious in the treatment of clinical legionellosis.
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Table 5.1 LD5 0 values for L. pneumophila in the embryonated
hen’s egg.

Route of Inoculation

cfu/ml

allantoic s a c

5.5 x 10 4

amniotic s a c

1 .4 x 102

chorioallantoic m em brane (CAM)

3.3 x 104

yolk s a c

6 .6 x 102
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Table 5.2 Histopathological observations on organs of embryos
inoculated with 1, 10, 100 or 1000 times the YSLD 5 0 of U
p n eum op hila.

Days post-inoculation
1, 2, 3, 4

5,

6

, 7,

81

Feature
systemic degenerative changes
in organs

+++

edem a

+++

congestion of blood vessels

+++

cellular dam ag e

+++

inflammatory cell response

+++

+++ = extensive dam age, - = not found
1All features described reflect findings with inoculas of 1, 10 and 100 times the

Y S L D 50 with the exception of 1 0 0 0 Y S L D 5 0 , which were found at four days post
inoculation.
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Table 5.3 Ultrastructural observations on cells of embryo organs
inoculated with 100 times the YSLD50 of L. pneum ophila.

Cell

Days post-inoculation

Damage

4 ,5

1, 2
Breakdown of cell a n d nuclear membrane

++++

Cytoplasmic clearing

++++

Fatty degeneration

++++

Ballooning of nuclear mem brane

++++

Pyknosis

++++

Karyolysis

++++

Mitochondrial d a m a g e

+++

Margination of chromatin and nuclear

++++
++++

clearing
Intercellular sp a c e s a n d cellular vacuoles

++++

Hemolysis

++++

++++ = extensive in all cells examined;
+ = rarely found; - = never found
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+++ = common in many cells;

Table 5.4 Appearance of inflammatory cells in chick embryo
organs infected with 100 times the YSLD 5 0 of L. pneumophila and
protected with 10 times the MIC of each antibiotic.
Antibiotic

MIC (pg/m l)

control (100 YSLD5o)

Days post-inoculation

5

ciprofloxacin

0.08

8

doxycycline

0.80

6

erythromycin

0.50

6

rifampicin

0.03

6
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Table 5.5 Ultrastructural cell damage in embryo organs previously
inoculated with 100 times the YSLD50 of L. pneumophila
and protected with antibiotic

Antibiotic

MIC
(pg/ml)

Days post-inoculation

Dose administered
per egg 1 (pg/ml)

4
(1 day post
therapy)

8
(5 days post
therapy)

Ciprofloxacin

0.08

28

+++2

+

Rifampicin

0.03

10.5

+++

+++

Erythromycin

0.50

175

+

Dead

Doxycycline

0.80

280

+

Dead

iD ose per egg was b ased upon 10 times the MIC for each drug and an average
egg volume of 35 mis.
2Degree of ultrastructural d am ag e observed, +++= marked, += slight
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Figure 5.1 Schematic illustrating various routes of inoculation and compartments
of the chick embryo.
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Chorio-allentoic membrane route

False air sac

A ir displaced
from sac

Figure 5.2 Schematic illustrating the chorioallantoic route of inoculation of the
fertile h e n 's egg.
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Figure 5.3 Bacterial viable counts a s s a y s on embryo organs from e g g s inoculated
with th e YSLD50of L. pneumophila. Note rapid bacterial growth in all organs
examined. Organisms were found most concentrated in the liver.

142

L iv er
H eart
S p le e n
K id n e y

3

4

S

6

7

8

9

days post-inoculation

Figure 5.4 Bacterial viable count assay s on embryo organs from e g g s inoculated
with 10 times the YSLD50 of L. pneumophila. Note increased bacterial growth rate
in all organs examined. The liver contained the d e n s e st microbial population.
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Figure 5.5 Bacterial viable count assays on embryo organs from e g g s inoculated
with 100 times the YSLD50 of L. pneumophila. Bacterial growth in o rgan s was
similar in all organs examined but was less rapid than growth in o rg an s of embryos
inoculated with 10 times the YSLD50.

144

~i ----------------- 1----------------- 1-----------------

4

5

6

•—

H eart

o—

S p le e n

• —

K id n e y

1----------------- 1-----------------

7

8

9

days post-inoculation

Figure 5.6 Bacterial viable count a s s a y s on embryo organs from egg s inoculated
with 1000 times YSLD50 of L. oneumoohila. Note increased bacterial growth in
liver and heart tissue after 6 days post-inoculation.

10

I

c fu /G R A M

10

□
O

10

10

□I
■I

•

LIVER

□

HEART

■

SPLEEN

O

KIDNEY

o

o
o

□

□
□

I

o
O

1 MIC

O

10 MIC

10
PBS

ERY

RIF

C IP

ERY

RIF

C1P

A N T IB IO T IC

Figure 5.7 Bacterial growth of L. pneumophila in embryo organs previously
inoculated with 100 tim es the YSLD50and treated one day post-inoculation with
1 or 10 tim es the MIC of antibiotic. Treatment with ten times the MIC of
ciprofloxacin was most effective at reducing bacterial growth in the majority of
organs examined.
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Figure 5.8 Viability rate of embryos previously infected with 100 times
theVSLDso of L. pneumophila and treated with 10 times the MIC of each
antibiotic. P B S control (o), ciprofloxacin (■), erythromycin ( ^ ) and rifampicin
(□)■ Ciprofloxacin was the most efficacious antibiotic u se d in th ese trials.
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Plate 5.1 Histological sections of liver tissue from the chick embryo.
Hematoxylin and eosin stain.
a) normal tissue with dispersed red blood cells (RBCs) (X 165), b) liver tissue
five days after inoculation with the VSLD50 of L. pneumophila. Note edem atous
tissue and densely staining inflammatory response within co n g ested central
vein (X660).
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Plate 5.2 Histological sections of heart tissue from the chick embryo.
Hematoxylin and eosin stain.
a) normal tissue (X 165), b) heart tissue five days after inoculation with the
YSLD50 of L pneumophila with marked vascular congestion (arrows) (X 165).
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Plate 5.3 Histological sections of spleen from the chick embryo. Hematoxylin
and eosin stain,
a) normal tissue (X 165), b) spleen 5 days after inoculation with the YSLD 50 of
L. pneumophila. Inflammatory cells are evident within central artery and
surrounding tissue (X165).
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Plate 5.4 Histological sections of kidney from the chick embryo. Hematoxylin
and eosin stain.
a) normal tissue showing glomeruli, convoluted tubules and circulating RBCs of
the kidney (X 165), b) kidney five days after inoculation with the YSLD 50 of L
pneum ophila. Note d a m a g e d sustained by glomeruli (short arrow) as
compared to the convoluted tubules (long arrow). Inflammatory cells are
distributed thoughout tissu e the tissue (X 660).
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Plate 5.5 Histological section of liver at five days post-inoculation at high
magnification showing influx of inflammatory cells. Note incidence of PMNLs
(short arrow) an d lymphocytes (long arrow) a s well a s d am ag ed hepatocytes (X
1650). Hematoxylin and eosin stain.
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Plate 5.6 Electron micrograph of kidney three days after inoculation with 100
times the YSLD50 of L. pneumophila. Subtle pathological c h an g es within the
mitochondria of cells were evident at this time (arrows) alongwith fatty
degeneration an d vacuole formation (X 8,000). Bar=1 pm.
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Plate 5.7 Electron micrograph of heart th ree days after inoculation with 100
times the VSLD50 of L. pneumophila. Note extreme d a m a g e to mitochondria
(arrows) and initial stages of cytoplasmic clearing (X 10,000).
Bar=1 pm.
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Plate 5.8 Electron micrograph of spleen four days after inoculation with 100
tim es the YSLD50 of L. pneumophila illustrating ballooning of nuclear
m em branes (short arrow), margination of chromatin material (long arrow),
vesicle formation within cytoplasmic s p ace (open arrow) and the presence of
"ghost mitochondria" (curved arrow) (X 6,000). Bar=5 |4.m.
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Plate 5.9 Electron micrograph of kidney four days after inoculation with 1 00
times the YSLD50 of L. pneumophila. Note the various s ta g e s of the hemolytic
process (X 8,000). Bar =1 pm.
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Plate 5.10 Electron micrograph of liver five d ay s after inoculation with 100 times
the YSLD5o of L. nneumophila illustrating advanced s ta g e s of the infection.
Necrotic hepatocytes are bordered by hemolysed RBCS. Cell m em branes of
liver cells are intermittently lysed (X 4,000). Bar=5 pm.
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Plate 5.1 1 Electron micrograph of heart five days after inoculation with 100
times the YSLD 50 of L. pneumophila showing pathological ch an g es at this
stage of the infection. Fatty degeneration, intercellular and intracellular
clearing, margination of chromatin material and m em brane lysis are apparent
(X 4,000). Bar=5 \xm.
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Plate 5.12 Electron micrograph of spleen five d a y s after inoculation with 100
times the YSLD 50 of L. pneumophila. Pyknosis (short arrow) and karyolysis
(long arrow) of nuclei are evident alongwith the formation of many cytoplasmic
vesicles (X 6,000). Bar=5 pm.

Plate 5.13 Electron micrograph of spleen tissue four days after inoculation with
100 tim es the YSLD50 of L. pneumophila. Cell with intracellular organism
associated with cellular and sub-cellular pathology (X 8,000). Inset: higher
magnification of L. oneumoohila organism (X 20,000). Bars=1 pm.

Plate 5.14 Electron micrograph of kidney from embryos treated with 10 times the
MIC of erythromycin three days after bacterial infection. Thin-sectioned tissue at
four d ay s post-infection (one day post-therapy) showing improved tissue a s
com pared to untreated controls at the sam e sta g e of infection. Erythromycin did
not sustain this level of activity with time (X 10,000).
Bar=l pm.
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Plate 5.15 Electron micrograph of kidney from embryos treated with 10 times the
MIC of doxycycline three d ay s after bacterial infection. Thin-sectioned material
at four days post-infection (one day post-therapy) illustrating improved
presentation of tissue a s com pared with untreated controls at the sa m e stage of
infection. Doxycycline w as not able to maintain this level of activity with time ■
(X 8,000). Bar=1 urn.
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Plate 5.16 Electron micrograph of kidney from embryos treated with 10 times
th e MIC of rifampicin three days after bacterial infection. Thin-sectioned
material at four days post-infection (one day post-therapy). Rifampicin treated
tissue showed som e improvement a s com pared to untreated tissue at the sam e
stag e of infection (X 4,000). Bar=5 (a.m.
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Plate 5.17 Electron micrograph of kidney from embryos treated with 10 times the
MIC of rifampicin three days after bacterial infection. Thin-sectioned material at
eight days post-infection (five days post-therapy). No improvement of the
condition of the tissue w as noted with time (X 4,000). Bar=5 pm.
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Plate 5.18 Electron micrograph of liver from embryos treated with 10 times the
MIC of ciprofloxacin three d ays after bacterial infection. Thin-sectioned material
at four days post-infection (one day post-therapy) exhibiting no significant
improvement of tissue condition a s compared to untreated controls at the sam e
stage of the infection (X 4,000). Bar=5 pm.
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Plate 5.19 Electron micrograph of liver from embryos treated with 10 times the
MIC of ciprofloxacin three days after bacterial infection. Thin-sectioned material
at eight days post-infection (five days post-therapy). Note much improved
condition of tissue a s compared with treated embryos at 4 days post-infection (X
4,000). Bar=5 pm.

166

Section VI
6.

General Discussion
Data from th ese studies indicated that a molecule or molecules with lectin

like activity on the surface of this organism may be responsible, at least in part, for
L. pneumophila binding to host target cells. Further identification and isolation of
L. pneumophila surface structures which facilitate attachm ent to target cells may
lead to the development and production of potentially useful anti-adherence
vaccines. The process by which L. pneumophila recognized and adhered to host
cell su rfaces represents the earliest, most critical stage of bacterial infection. The
ability to block these initial events with such prophylactic treatm ents would
illustrate a novel strategy for the prevention of clinical legionellosis.
The chick embryo w as established a s a powerful tool for the evaluation of L
pneumophila virulence and proved a viable alternative to other animal system s for
the study of the pathology and chemotherapy of the extrapulmonary manifestations
of experimental L. pneumophila infections. B ecause of the intracellular nature of
this organism, in vitro MIC data do not reflect in vivo or clinical results. These
studies dem onstrated the fertile hen's egg a s a readily accessible in vivo system
for the evaluation of putative antimicrobial therapy for legionellosis and may prove
of significant value for the evaluation of antibiotic regimens for other facultative
intracellular pathogens such as Brucella. Yersinia. Listeria. Chlamydia and many
others. Although, erythromycin (the drug of choice for Legionnaires' disease),
rifampicin an d doxycycline showed antimicrobial activity in this animal system,
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ciprofloxacin, a newer broad spectrum quinolone antibiotic was the most
efficacious in th ese trials.
Studies which characterized the morphological response of L. oneumoohHa
to clinically relevant antibiotics provided indicators of the bacteriostatic versus
bactericidal nature of th ese agents and yielded som e information concerning the
structural nature of the organism. In addition, examination of the microbial dam age
induced by selected antimicrobials was necessary for the interpretation of results
derived from further in vivo evaluations of these antibiotics.
L. pneumophila is a human pathogen that c a u s e s fatal disease.
Immunocompromised individuals are particularly susceptible to infection and
respond variably to the current antibiotic regimens. The present investigation
partially characterized the adherence of L. pneumophila to host cells and explored
the possibilities of novel preventative m easu res in the form of anti-adherence
vaccines for human disease. Furthermore, th ese data delineated the
pathogenesis and pathology of L. pneumoohila in experimental animal infections
and illustrated the role of clinically relevant antibiotics in the outcome of disease.
T hese results may lead to the development of aggressive combination therapeutic
regimens in which protective vaccines and new broad-spectrum antimicrobial
a g en ts can be used for the prophylaxis and control of clinical legionellosis. Finaily,
this work clearly dem onstrated the superior antimicrobial activity of the quinolones
and their potential for treatment of human Legionnaires' disease.
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Section VII
7.

Possible future studies:
This work h as taken a number of interesting turns and h as revealed a variety of

problems which could usefully be ad dressed concerning the further characterization of
the pathogenesis of L. pneum ophila:
1 ) role of humoral and cell-mediated immunity of the chick embryo to L.

pneumophila infection and the outcome of disease.
2 ) examination of the potential intracellular colonization of the inflammatory

cells reported here by L. pneumophila.
3) characterization of the role of L. pneumophila toxins in the disease process
in the chick embryo.
4) role of bacterial toxins and antibiotics in intracellular survival of L.
p neum ophila.
5) com prehensive characterization of specific L. pneumophila adhesins (outer
m em brane proteins, fimbriae, pili, lectins) involved in ad h eren ce to host ceils.
6 ) identification of host cell receptors for L. pneumophila.

7) electron microscopic examination of L. pneumoohila adheren ce to U937 and
s u bsequ en t internalization processes.
8) effect of selected antibiotics (especially at sub-MIC levels) on L
pneumophila adherence to host cells.
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9) evaluation of im munosuppressive regimens on the outcome of experimental
legionellosis in the chick embryo system.
10) determination of the synergistic action of selected antimicrobial agents in
vitro and in vivo.
11) characterization of the m echanism s of L. pneumophila uptake by host cells
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APPENDICES
Appendix 1
Media used in biological studies.
1. Cell cultures
1.1 De-ionized water
All water used to make up media was obtained from a Millipore Milli Q
filtration system. Ten Megohm water was collected, filter sterilized through a 0.2
pm filter, and one liter aliquots stored at 4° C.
1.2 P h o sp h a te buffered saline (PBS\
Solutions of PBS were made in de-ionized water a s follows and
sterilized by autoclaving and stored in 100 ml aliquots in glass bottles at 4° C.
c o m ponent

grams/liter

NaCI
KCI
KH2P 0 4
Na2H P 0 4

8.0
0.2
0.2
0.15

1.3 H anks’ Balanced Salt Solution (HBSS)
A concentrated 10 X sterile solution of HBSS with 0.35 g/l sodium
bicarbonate and phenol red w as obtained from Irvine Scientific. For use, the
stock solution was diluted ten-fold under aseptic conditions with sterile
de-ionized water. The stock and working strength solutions were stored in
sterile g la ss bottles at 4° C.
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1.4 Sodium bicarbonate solution (NaHCCh)
A stock 7.5 % solution of sodium bicarbonate was m ade by dissolving 75
g NaHC 0 3 in 1 liter of de-ionized water and sterilized by filtration. Aliquots of
100 mis were placed in sterile bottles and stored at 4° C.
1.5 Bovine calf serum
Sterile bovine calf serum supplem ented with iron w as obtained from
Hyclone Laboratories, distributed in 50 ml volumes in sterile plastic tubes and
stored at -20° C.
1.6 Glutamine
This w as obtained in powdered form from Sigma, dissolved in sterile
de-ionized water to make a 100 X stock (300mM) solution an d filter sterilized.
Aliquots were stored at -20® C.
1.7 Minimal Essential Media with Earles salts and non-essential amino acids
(MEM)
This medium w as obtained from Irvine Scientific as a sterile 10 X
concentrated solution with added phenol red.

For use, stock solutions were

diluted ten-fold with sterile de-ionized water in an aseptic m anner. Stock and
working strength solutions were stored in sterile glass bottles at 4° C.
1.8 Trvosin-EDTA
Trypsin and sodium versenate (EDTA) w ere obtained in powdered form
from Sigm a and dissolved in 100 ml of warm PBS to make a working solution of
0.05% trypsin and 0.02% EDTA. Aliquots of 10 ml were stored at -20°C.1.8
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Growth medium
MEM with Earles salts was prepared with the following sterile
constituents:
C om ponent

Volume

MEM with Earles salts
Bovine calf serum
Sodium Bicarbonate (7.5%)
Glutamine

450 ml
50 ml
10 ml
5 ml

2 . O rg a n is m growth

2.1 SaiicLmedium
Buffered yeast extract agar supplemented with a-keto glu tarate (BCYEa)
was obtained from Gibco Laboratories (Madison, Wisconsin) and prepared
according to the manufacturer’s instructions.

Components of this medium were

a s follows:
C om ponent

grams/liter

y east extract
ACES buffer
ferric pyrophosphate
a -k e to g lu ta ra te
agar
charcoal, activated

10.0
10.0
0.25
1.0
15.0
2.0

Four ml of a filter sterilized solution of 10% L-cysteine HCI was then aseptically
added to 1 liter of medium according to manufacturer's instructions.
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2.2 Broth medium

Buffered yeast extract broth supplemented with a-ketoglutarate (BYEa)
was prepared a s follows:
C om ponent

grams/liter

yeast extract
ACES buffer
ferric pyrophosphate
a-k e to g lu ta ra te

10.0
1 0 .Q
0.25
1.0

Constituents were added to one liter of distilled water, allowed to
dissolve, filter sterilized through a 0.2pm filter and collected aseptically. Four mi
of a filter sterilized 10% solution of L-cysteine HCL w as aseptically added to the
medium prior to use.
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A p p e n d ix 2

1.

Reagents and materials used in histological studies.

1.1 Harris' Alum Hematoxylin
This solution was comprised of the following:
C om ponent

Amount

hematoxylin crystals
absolute alcohol
aluminum ammonium sulfate
de-ionized water
mercuric oxide

5.0 g
50 ml
100 g
1000 ml
2.5 g

Hematoxylin crystals were dissolved in alcohol and the aluminum ammonium
sulfate dissolved in water. The two solutions were then mixed and rapidly
brought to a boil.

Mercuric oxide was added slowly and the mixture reheated

for 15-20 min. This w as kept covered in a glass coplin jar ready for use.
1.2 Stock 1% aqu eo us eosin solution
The following com ponents comprised this solution:
C om ponent

Amount

water soluble eosin
de-ionized water
glacial acetic acid

10 g
1000 ml
2.0 ml

This were mixed and the solute allowed to dissolve. The stock solution was
kept in a glass stoppered bottle and stored at 20° C.

A working solution was

m ade by mixing 50 ml of the stock solution with 120 ml absolute alcohol, 30 mi
de-ionized water and 1.0 ml glacial acetic acid.
1.3 Acid alcohol solution
This w as m ade by adding 70% (710 ml of 95%alcohol with 290 ml
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deionized water) to 10 ml concentrated hydrochloric acid, and stored in a
stoppered bottle at 20° C.
1.4 Saturated lithium carbonate
This w as m ade by dissolving 4.5 g of lithium carbonate in 450 mi d e
ionized water and stored in a stoppered bottle at 20°C.
1.5 Buffered formalin solution
A 10% solution of formaldehyde (VWR) was prepared in PBS and stored
in a stoppered g lass bottle at room temperature.
1.6 Preparation of histological sections
Tissue sam ples were harvest from embryos and fixed in 10% buffered
formalin. Sam ples were then em bedded In paraffin with a Lab Tek Tissue
P rocessor and trimmed with a razor blade. Four micron sections were cut with a
American Optical rotary microtome, attached to glass slides and prepared for
staining.
1.6.1 Hematoxylin and eosin staining procedure
The following staining procedure was used:

Treatment

Time

Histoclear (two changes}
100% alcohol (two changes)
95% alcohol (two changes)
de-ionized water
Harris' Hematoxylin
Running tap water
Acid alcohol
de-ionized water
lithium carbonate
running tap water
eosin
95% alcohol (two changes)
100% alcohol (two changes)

2 min
1 min
1 min
3 dips
6 min
2 min
6-8 dips
3 dips
7 dips
15 min
1 -4 min
15 sec
15 sec
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Appendix 3
R eagents and m aterials used in electron m ic ro s c o p y studies.

1.

N e g a tiv e staining

1.1 Grids
Copper 400 mesh grids were supplied by Electron Microscopy Sciences
(EMS) and w ere used in all studies.
1.2 Formvar
This w as obtained from EMS as a dry powder. A stock 2% solution was
m ade by dissolving one gram of formvar in 50 ml electron microscopy grade
ethylene dichloride (EMS).
upon standing overnight.

Remaining solid after vigorous shaking dissolved
Stock solution was stored in glass stoppered bottles

in a desiccator until use.
Working solution w as made up freshly as a 0.2% solution by mixing 18
ml ethylene dichloride with 2 ml stock formvar solution.
1.3 Formvar coating of grids
A clean dry glass slide was dipped into 20 ml 0.2% working strength
formvar solution in a Coplin jar, removed and drained. When dry, the film was
cut in situ into suitable sized squares using a sharp scalpel, and th e s e sq u ares
were floated off onto the surface of de-ionized water by carefully submerging at
a shallow angle the formvar coated slide. In reflected light, the formvar films
could be s e e n a s pale opalescent sq uares floating on the surface of the
de-ionized water. Copper grids were placed (matt side down) on top of the films
an d collected from the water by carefully placing pieces of Whatman No. 1 filter
pap er over the films. Filter papers with adherent formvar films and grids were
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collected and dried.

1.4 Phosphotunastic acid fPTA) negative stain
A 1% (w/v) solution w as made by dissolving potassium
phosphotungstate in 100 ml de-ionized water and the pH was adjusted to 6.7
using fresh aq u eo u s potassium hydroxide. Any turbidity remaining after
standing at room temperature for 24 hours was removed by centrifugation at
10,000 RPM in a Beckman Microfuge 12. The stain w as stored at room
tem perature an d used a s required.
1.5 Negative staining procedure
Equal volumes of a bacterial suspension of approximately 5 x106 cfu/ml
w ere mixed with 1% PTA on a glass slide and a drop of the resultant mixture
w a s placed onto a formvar coated grid. The mixture was allowed to remain on
the grid for about 10-15 seco n d s before being drained off by touching the edge
of th e grid with a piece of Whatman No. 1 filter paper. The rate at which the
bacteria-stain mixture drained from the grid into the filter paper w as indicative of
th e suitability of the preparation. Drops that drained quickly usually contained
insufficient material.
2.

E m be d c in g and th in-sectio nin g

2.1 Grids
EMS 400 mesh copper grids were used in all studies.

193

2.2

Cacodvlate buffer
This was m ade by adding the appropriate amount of sodium cacodylate

(EMS) to one liter of de-ionized water to give the following concentrations:
S a m p le s

Concentration

bacteria

0.05 M (supplemented with10mM

tissue

0.10 M

M g S 0 4)

T hese solutions were adjusted to a pH of 7.2 using hydrochloric acid and stored
at 4 o C until required.
2.3 G.lutaraldehvde
Glutaraldehyde was obtained from EMS as an electron microscopy
grade 25% (v/v) aqu eo us solution. The stock solution w as stored in at 4° C and
working 3% (v/v) solutions were m ade freshly in cacodylate buffer a s required.
2.4 Osmium tetroxide
A stock 2% (w/v) solution of OSO 4 (Stevens Metallurgic Corporation) was
m ade by dissolving the contents of a ig ampule in 50 ml cacodylate buffer.
OSO 4 emits a d angerous vapor and was always handled in a fume hood. The
solute w as completely dissolved after standing overnight at 4° C. The stock
solution was stored at 4° C in a tightly capped bottle covered with aluminum foil.
The working 1% solution was m ade by mixing equal volum es of the stock 2%
solution and cacodylate buffer.
2.5 Ethanol series
A graded ethanol series w as made by mixing appropriate am ounts of dry
absolute ethanol and cacodylate buffer. The 50% and 70% solutions were
stored at 4 o C and the 90%. 95% and absolute ethanol solutions w ere stored at
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room temperature. (Percentages refer to the concentration of ethanol).
2.6 Propylene oxide
This w as obtained from EMS and was supplied ready for use. The
container w as kept tightly stoppered at all times.
2.7 Resin mixture
The resin used in all studies is described in 2.7.1 below. All volumes
w ere m easured in disposable 50 ml tri pour beakers from VWR except for
dibutyl phthalate and DMP-30 which were m easured using one ml disposable
syringes without needles.
2.7.1 Epon-araldite resin mixtur£
The resin mixture w as comprised of the following:
C o m p o n en t

Proportion

1) Epon 812 (resin)

5 parts

2) Dodecenyl succinic anhydride (DDSA)

11 parts

3) Araldite (resin)

3 parts

4) Dibutyl phthalate (plasticizer)

0.8 parts

5) Methyl nadic anhydride (DMP 30) (accelerator)

0.4 parts

C om ponents were added to a glass bottle in this order and vigorously shaken
for 10 min with the exception of DMP 30 which w as added just before resin was
required for use. Complete resin (with DMP-30) w as then vigorously shaken for
a n additional three to five min. This resin mixture was polymerized at 60° C for
24 h.
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2.8 Em bedding and thin-sectioning procedure

For bacterial samples, organisms were harvested, fixed in 3% buffered
glutaraldehyde, w ashed three times in 0.05 M cacodylate buffer containing
lOrnM MgSC>4 and pre-em bedded in 3% (w/v) Noble agar. Cubes of 1

m m 3

:hickness were cut and post-fixed in 1 % OSO 4 in cacodylate buffer for 1 h.
Tissue sam ples were harvested, rinsed in 0.1 M cacodylate buffer and
fixed in 3% buffered glutaraldehyde. One mm3 cubes were cut and post-fixed in
1% OSO 4 in cacodylate buffer for 1 h,

All sam ples were rinsed in cacodylate

buffer three times followed by a dehydration procedure of immersion for five
min in each of 50%, 70%, 90% and 95% ethanoi in cacodylate buffer.
Dehydration of sam ples was completed by two rinses of ten min e a c h in
absolute alcohol. Ethanol was removed by pipette and the specim ens rinsed
twice in propylene oxide. Specim ens were not allowed to dry during any step of
this procedure.
Resin infiltration w as done by placing the sam ples in a 2:1 mixture of
propylene oxide and complete resin for one hour, and this mixture w as then
replaced by a 1 :2 mixture of propylene oxide and complete resin for an
additional hour. Specim ens were placed in complete resin for one hour after
which the resin w as changed for fresh complete resin which had been
d e g a s s e d for 20 min in a vacuum desiccator.

These remained in the d e g a s se d

resin for one hour, removed and located in embedding molds. The molds were
filled with d e g a s s e d complete resin. Specim ens were manipulated using
wooden swab sticks sharpened at one end to form a flexible spatula which was
pre-treated by dipping in d e g a s se d complete resin. T hese treated spatulas
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were placed at 60° C for one hour prior to use to allow the resin end to dry and
so a s to prevent the introduction of air bubbles around the specimen. Blocks
were labelled with hardened paper and polymerized in a 60° C oven for 24 h.
After removal from the oven, blocks were left at room tem perature for two or
three days to allow complete hardening of the resin prior to their removal from
the molds. Embedding of samples w as completed in one day and was followed
by a 24 h polymerization, the whole procedure taking approximately 30 h to
complete. The embedding schedule and times required are summarized in
Table 1.
Polymerized blocks were placed in the round chuck of a LKB Ultratome III
ultramicrotome and trimmed mechanically with a glass knife m ade with an LKB
knife maker.
When blocks had been appropriately trimmed, ultra thin sections were
cut using the thermal advance on the ultramicrotome and using a Diatom
diamond knife filled with clean de-ionized water. The diamond knife edge v. as
cleaned with a soft clean pith stick. Sections giving grey or silver interference
colors (60-90 nm thickness) were chosen. Individual sections an d small
ribbons were picked up on copper grids. Grids were subm erged in the boat and
sections located above them with a mounted eyelash. Sections were removed
by lifting the grid out of the water and the grids blotted dry by touching the edge
to a piece of filter paper.
Ultrathin sections were stained with 5% aq ueou s uranyl acetate for 60
seco nd s by floating grids, sections downward, on a drop of stain placed on
parafilm and covered by a glass petri dish lid. Grids were removed and
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sections w ashed thoroughly in a running stream of de-ionized water using
approximately 15 ml per grid, after which they were blotted and allowed to dry.
The grids were then held in fine forceps and a drop of lead citrate placed on
them for 20 seconds, after which they were w ashed as before using
approximately 25 to 30 ml de-ionized water per grid. Grids were blotted and
allowed to dry a s before, Stain was removed from the stock bottles using a fine
p aste u r pipette with the tip located about 5mm below the meniscus. The first
drop in the pipette was always discarded, th u s ensuring minimal stain deposit.
Thin-sectioning was performed under strictly dust free conditions and all
materials coming into contact with sections, knife or boat w ater were stringently
clean ed and rinsed under running de-ionized water. Sections were exam ined
a n d photographed in a Hitachi H600 electron microscope at 75 kV, using
various instrumental manipulations.
2.9 Stains for ultra thin sections
2.9.1 Urany! acetate
A 5% (w/v) solution of uranyl acetate w a s made by dissolving 1 g in 20 ml
de-ionized water. The solid w as found to dissolve completely upon standing
overnight at room temperature. The solution w as filtered through a Whatman
No. 2 filter paper and stored in a dark glass-stoppered bottle at room
tem perature.
2.9.2 Lead citrate
One pellet sodium hydroxide was dissoved in 15 ml boiled cooled d e 
ionized water. This solution w as added to 0.1 g lead citrate in a glass screwc ap p ed bottle and dissolved by shaking. A further 10 ml boiled cooled de-
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ionized water was added, and the stain was stored tightly capped at room
temperature.
3.

S c a n n in g electro n m ic ro s co p y (SEM)

3.1 Hexamethvldisilaxane (HMDS1
This was obtained from Polysciences, Inc. (Warrington, Pa.) and kept
tightly capped in a fume hood prior to use.
3.2 SEM procedure
Bacterial specim ens were fixed in 3% glutaraldehyde in cacodylate
buffer, w ashed three times in buffer and dehydrated in 50%, 70%, 90%, and
absolute ethanol. Sam ples were then treated with two ch an g es of HMDS and
applied to specimen stubs with double sided sticky tape. Stubs were coated
with 20 nm gold/palladium at a target to specimen distance of 5 cm with a
current of 15 mA for 4 min.

Specim ens were viewed in a Hitachi H600 electron

microscope in the scanning mode at an accelerating voltage of 40 kV.
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Table 1 .

E m bedding of specim ens fo r electron m icroscopy.

P rocedure

T im e

1) W ash in cacodylate buffer

15 min

2)

30 min

Fix in 3% glutaraldehyde in cacodylate buffer

3) W ash in cacodylate buffer (ten changes)

30*40 min

4)

Post*fix in 1% OsC >4

1h

5)

W ash in cacodylate buffer

5 min

6 ) Dehydrate in ethanol series in cacodylate buffer

20 min

7)

40 min

Complete dehydration in absolute ethanol
and propylene oxide

8 ) Resin / propylene oxide mixtures

120 min

9)

120 min

Resin (two ch ang es)

10) Polymerization

24 h

Total Time Required

Approximately 30 h
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Appendix 4
1.

Production of polyclonal antisera against L. pneu mophila.

1.1 Babbits
White New Zealand rabbits were obtained locally and pre-bled to a s s e s s
pre-immunization level of antibodies against L. pneum ophila.
1.2 Antigen preparation
Whole cells of L, pneumophila (approximately 1 x 1 0 9 cfu/ml) were
formalin fixed in 1% (v/v) formaldehyde (VWR) in PBS and a small volume of
sterile egg yolk. Prior to immunization of rabbits, 1 ml of this solution w as mixed
with an equal volume of Freund's Incomplete adjuvant (VWR) and
hom ogenized in a Sorval Omni Mixer.
1.3 Bleeding procedure
1.3.1 Ear bleed
S am ples of blood obtained for antibody titer analysis following
immunization were drawn aseptically from the central artery of one of the
rabbit's ears. Vasodilation of this artery was achieved by warming the rabbit's
e a r with a 15 watt bulb of a portable lamp.

When the artery w a s suitably

dilated, the e a r was sw ab b ed with alcohol and a 21 gauge needle was inserted
to release approximately 5 ml blood into a sterile test tube. The ear was then
sw abbed again with alcohol and treated appropriately to stop the bleeding.
1.3.2 Cardiac puncture
Once the antibody titer had reached a suitable level following
immunization, the final volume of blood was collected by cardiac puncture and
exsanguination of the rabbit. The rabbit was anesthetized with the addition of a
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sodium solution of Nembutal into the peripheral vein of the ear and blood
drawn through an 18 gauge needle and syringe inserted through the chest
cavity into the heart. The rabbit was exsanguinated in a hum ane fashion with a
final injection of Nembutal into the heart.
Blood obtained from ear bleeds and cardiac puncture w as allowed to clot
overnight at 4o C and the resultant serum decanted for titer analysis or stored
frozen in 1 ml aliquots at -70° C.
1.4 Antibody titer a ssay
An indirect immunofluorescence assay (Materials and Methods, Chapter
Four) w as used to m easure the titer of sera drawn from rabbits. Once obtained,
doubling dilutions of the serum were m ade in PBS and used immediately in the
analysis. Formalin fixed whole L pneumophila cells were ad d ed to multiple
spots on glass slides and allowed to dry. Dilutions of the serum were ad ded to
th ese a r e a s as the primary antibody in an indirect immunofluorescence a ssay
and allowed to incubate at 37° C for 1 hour. Three-fold w a s h e s were m ade with
PBS whereupon goat anti-rabbit FITC conjugated serum was ad d ed to all spots
on the glass slide and incubated for 1 hour at 37° C. These w ere washed three
times and viewed with an BH-2 Olympus microscope in the
immunofluorescence mode. Appropriate scores of immunofluorescence for
each dilution were m ade and the most diluted spot which gave a positive score
selected a s the titer.
1.5 Immunization procedure
Rabbits were pre-bled and analyzed for pre-immunization antibody
against L. pneumophila. A small area of the rabbits back w as clean shaven,
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swabbed with alcohol and the antigen-adjuvant mixture administered into 10
sub-cutaneous sites with a 21 gauge needle and syringe. T hese sites were
sw abbed with alcohol again and examined for unusual reactions. The rabbits
were boosted with a similar antigen m ass 2 and 4 weeks later. Antibody titer
was checked every week during this time.
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